A丝ter January 1, 1997, a page charge of $35 per printed page was levied on all manuscripts published in Clinical Cancer Research. It is understood at the time of submission that the author(s) agree to pay this charge in the event of publication. Under exceptional circumstances, when no other source of grant or other support exists, the author(s) may apply to Dr. Margaret Foti, Director of Publications, AACR Publications Department (see page ii for address) at the time of submission for a waiver of the page charges. All such applications must be countersigned by an appropriate institutional official stating that no funds are available for the payment of page charges.

Annual Meeting

The AACR’s Annual Meeting is one of the largest and most important annual gatherings of scientists engaged in cancer research worldwide. The next Annual Meeting will take place in New Orleans, LA, March 28–April 1, 1998. The Chairperson of the Annual Meeting is Frank J. Rauscher III of the Wistar Institute. The Program Committee will invite outstanding scientists in the field to organize plenary sessions, symposia, controversy sessions, and meet-the-expert sunrise sessions. They also look forward to receiving for consideration presentation the proffered papers submitted by members of the cancer research community. All abstracts must be sponsored by an AACR member in good standing. The deadline for receipt of abstracts in the AACR office will be October 28, 1997.

Call for Nominations for Honorary Membership

As stated in the Association’s By-Laws, “Honorary membership shall be open to distinguished scientists who have made extraordinary contributions to the advancement of cancer research, either through outstanding personal scientific activity, or through exceptional administrative leadership in cancer research.” Honorary membership in the AACR is reserved for a select, small group of investigators; there are currently only 20 honorary members in our total membership of more than 13,000. (See Page 1 of the current AACR Directory of Members for a list of Honorary members.)

The Special Committees Committee will review all candidates for honorary membership and will determine whether to recommend any candidates for election by the Board of Directors. Members wishing to make nominations for honorary membership should send a letter describing the outstanding achievements of the candidate. Since this person will be, by definition, a prominent researcher, the nominator does not need to supply a curriculum vitae or reprints. Nominations should be submitted by October 28, 1997, and may be sent to the Association Office.

AACR Minority Scholar Awards in Cancer Research Supported by the National Cancer Institute (CMBP)

Funds are being provided through the Comprehensive Minority Biomedical Program of the National Cancer Institute for the travel of a limited number of minority students to the 1998 AACR Annual Meeting. Eligible students from full-time predoctoral students, postdoctoral fellows, and physicians-in-training in the early stages of their careers who are either engaged in cancer research or who have training that could lead to contributions in this field.

AACR

The American Association for Cancer Research (AACR) was founded in 1907 to bring together active investigators of the cancer problem for the presentation and discussion of new findings and to foster advances in cancer research. Today the Association has 13,000 members working in all of the subspecialties of cancer research in the United States, Canada, and more than 60 other countries. Information on AACR programs and activities can be obtained from:

American Association for Cancer Research
Public Ledger Building
150 South Independence Mall West
Suite 826
Philadelphia, PA 19106-3483
Phone: (215) 440-9300
Fax: (215) 440-9313
E-mail: aacr@aacr.org

The AACR welcomes applications for membership from the researchers and scientists engaged in all areas of cancer research are eligible for membership. There are three categories of membership: active membership, open to cancer researchers working in the Americas; corresponding membership, to those working outside the Americas; and associate membership, to graduate and medical students, postdoctoral fellows, and physicians-in-training. Further information on the qualifications for each category as well as the benefits of membership can be found on the application forms at the back of this issue.

This travel award program applies only to minority groups that have been defined by the National Cancer Institute as being traditionally underrepresented in cancer research; these groups are Native Americans, African Americans, Hispanic Americans, Alaskan Americans, and Native Pacific Islanders. Only citizens of the United States and Canada or scientists who are permanent residents in those countries may receive one of these awards.

Preferential treatment will be given to authors of abstracts that have been accepted for presentation at the annual meeting, this is not a requirement for the award. Preference will also be given to new applicants. Awarded will be selected on the basis of their qualifications, references from mentors, and an estimation of the potential professional benefit to the Awardees. An advisory committee consisting of members of the AACR will review submitted applications and letters of reference. The award will consist of partial support of registration, travel, and subsistence expenses incurred in connection with attendance at the annual meeting.

Applicants will be chosen from minority institutions as well as the larger bodies of universities, colleges, and research institutes. Travel grants are awarded to the applicant’s institution to permit a minimum of four days of attendance at the annual meeting. If accepted, applicants will be expected to participate in all planned activities for the Awardees. They are required to submit a brief report commenting on the Minority Scholar Program and the scientific sessions they attended at the annual meeting.

Further information and application forms are available from the AACR Office. Letters of reference should accompany the application. The deadline for receipt of applications is December 1, 1997. Grants from this program are also available for attendance at AACR Special Conferences taking place across North America. The brochure for each meeting contains all the necessary information.

Gertrude B. Elion Cancer Research Award

Application forms for the AACR’s 1998 Gertrude B. Elion Cancer Research Award, supported by an educational grant from Glaxo Wellcome Oncology, will soon be available. This one-year, $30,000 grant to a nontenured Assistant Professor supports meritorious basic, clinical, or translational research in cancer causation, prevention, or treatment. Candidates for the award are expected to be current members in academia, federal government employees, and employees of private industry are not eligible for this award. The deadline for receipt of application information and application forms will be two weeks before the date of the AACR Special Conference and application forms will be mailed to AACR members and to those who requested application materials in the past as soon as they become available. Nonmembers who have not previously requested information or who have changed addresses should request information and application forms from the AACR Office.

AACR Research Fellowships

In 1998, the AACR will offer an enhanced program of supported fellowships for clinical and postdoctoral fellows. The basic, clinical, translational, and population fellowships will offer salary support at the level of $30,000 per year, with some fellowships extending for a term of two years. Eligibility has been expanded to include all citizens and permanent residents of any country in the Americas, who have completed the M.D., Ph.D., or other doctoral degree. Candidates must currently be a postdoctoral or clinical research fellow and must have been a fellow for at least two years but not more than five years prior to the year of the award. Medical residents, employees of industry, fellows with sponsorship for a similar program for the award year, and permanent employees of the federal government are not eligible. All Active Corresponding, Associate AACR members in the Americas will receive information and application forms by mail in the early Fall. Nonmembers may request information and application forms from the AACR Office. The deadline for applications will be early February, with the commencement of the award year on July 1, 1998.

AACR Special Conferences in Cancer Research

A number of meetings are now being organized in the AACR’s series of smaller scientific meetings. Following are the topics, dates, locations, and program committees for these meetings. When full details of each meeting are available, AACR members will be the first to receive complete brochures and application forms for participation in these important conferences. Nonmembers may receive this information by sending their names and addresses to: Meetings & Conferences, AACR, Public Ledger Building, Suite 826, 150 South Independence Mall West, Philadelphia, PA 19106-3483. Up-to-date program information is also available via the Internet at the AACR’s website (http://www.aacr.org/comrncf.shtml).

January 9–13, 1998
Molecular Mechanisms of Apoptosis Regulation
Chairpersons: JOHN C. REED, La Jolla, CA
VISHVA M. DIXIT, S. San Francisco, CA
Renaissance Esmeralda Resort, Palm Springs, CA

January 24–28, 1998
Angiogenesis and Cancer
Chairpersons: JUDAH FOLKMAN, Boston, MA
MICHAEL KLAGSBRUN, Boston, MA
Hyatt Orlando, Orlando, FL
First Announcement

89th Annual Meeting

American Association for Cancer Research

March 28 – April 1, 1998
New Orleans, Louisiana

An Exciting Multidisciplinary Program for Laboratory and Clinical Cancer Researchers

In This Booklet:
- Abstract Submission Forms and Instructions
- Preliminary Program Information
- Information on Awards for Young Basic and Clinical Investigators
- AACR Membership Application Forms
# Preliminary List of Topics for Symposia and Meet-the-Expert Sunrise Sessions

Inherited Cancer Susceptibility Syndromes: Genetics, Genes, and Function
Emerging Concepts in Individual Cancer Susceptibility
Tobacco and Lung Carcinogenesis: Genetics, Biology, and Etiology
Organ-Site Specific Tumorigenesis: Basic Science and Clinical Aspects of
  - Breast and Ovarian Cancer
  - Prostate Cancer
  - Gastrointestinal Cancer
  - Hematologic Malignancies
Tumor Physiology; Tumor-Stromal, Cell-Cell, and Microenvironment Interactions
An Integrated Approach to Angiogenesis: Inducers and Inhibitors from the Bench to the Bedside
Wnt Signalling Pathways in Human Tumorigenesis: APC/Beta Catenin/TCF-LEF
Cell Death Signalling Pathways: Caspase Cascades and Effectors/Initiators of Apoptosis
The bcl-2 Family: Regulation and Effectors
Transcriptional Regulation of the Neoplastic Phenotype
Developmental Biology-based Approaches to Tumorigenesis: Genetic Control of Pattern Formation and Organogenesis
Reconstruction of Human Tumorigenesis and Progression: Cancer Genetics in Model Organisms
New Concepts in Genome Damage in Cancer: Initiation and Progression
Molecular Determinants of Cellular and Tumor Responses to Radiation
New Mechanisms of Action of Viral and Cellular Oncogenes
Tumor Virology: Molecular Biology and Etiology
Genetic Approaches to Diagnosis: The Impact of Molecular Medicine on Early Detection and Diagnosis
The Molecular Basis of Immune Recognition: Basic Concepts with Therapeutic Implications
Advances in Cancer Vaccine Development
Successes in Oncogene-Based Drug Targeting: Selectivity and Specificity?
Molecular Diversity-based Approaches to Anticancer Drug Design
New Concepts in Antimetabolites: Basic Science and Clinical Trials
Restoring Drug Sensitivity to Tumors: New Concepts from Tumor Biology and Physiology
Progress in Cancer Gene Therapy: New Concepts/Targets and Clinical Trial Reports
Molecular Targets and Endpoints for Chemoprevention
The Latest in Telomere and Telomerase Function: Proof of Principle?
Histone (De) Acetylation and Chromatin Remodeling
DNA Repair
Advances in Drug Resistance: Basic and Clinical Growth Factor Signaling
Antisense in Clinical Trials
Nuclear Transports
Integrin Signaling
Metalloproteases
Radiation Sensitization
Myelodysplastic Syndrome
Cytokine Signaling
Cell Cycle Control
Leukemia and Solid Tumor Translocations
COX-2 Inhibitors
Nuclear Hormone Receptors
Chemoprevention Clinical Trials
Gene Transfer to Hematopoietic Progenitors
IL-12: Biological and Clinical Developments
Immunotherapy and Costimulatory Molecules
B-Cell Lymphomas
Emerging Issues in Molecular Epidemiology
Immunostimulatory Sequences
Mechanisms of p53 Action
IGF-1 and Cancer
Topoisomerases
Brain Tumors
Vascular Permeability
Animal Models for Chemoprevention Issues
Invasion and Metastasis
Carbohydrates and Cancer
Genome Project Update
Fidelity of DNA Replication
Psychosocial Aspects of Genetic Diagnosis
Melanoma
Taxanes, Epibotulins, and Tubulins
Antibody Therapy
Combination of Chemotherapy/Biotherapy
Be sure to fill out and return the acknowledgment card included with these instructions.
Dear Colleague:

On behalf of the President, Dr. Donald S. Coffey, and the 1998 Program Committee, it is my distinct pleasure to have this opportunity to introduce, highlight, and enthusiastically endorse our plans for the 89th Annual Meeting of the AACR in New Orleans, March 28-April 1, 1998.

I strongly urge you to submit an abstract of your most recent research and to participate in this most important function of the AACR's mission. As Chairperson of the Program Committee for the meeting, I have endeavored to assemble an outstanding scientific program which will deliver a comprehensive, state-of-the-art synthesis of the current progress, opportunities, and problems occurring in both basic and clinical aspects of cancer research. Our overriding goal has been to create a truly multidisciplinary program which will appeal to cancer researchers in all areas of expertise, spanning basic, translational and clinical research. As the war on cancer approaches the millennium, the constant crossfertilization of ideas and approaches utilized by investigators from diverse scientific disciplines will continue to catalyze our successes in this war. The AACR Annual Meeting has been and will continue to be the most important international gathering for stimulating and fostering these interactions. With the help of an outstanding Program Committee (see the inside back cover of this booklet), as detailed below, we have made a special effort this year to make your participation in the meeting both easier and more rewarding scientifically.

Our goals in designing and planning this meeting have been strongly influenced by the recognition that, recently, some of the most significant progress in cancer research has resulted from breakthroughs in very specialized and often narrow areas of the field as well as discoveries made possible by new collaborations across previously unrelated disciplines. In this climate, when scientific boundaries are changing and new research directions are emerging, attendance at the AACR Annual Meeting has become more important than ever. As always, the Annual Meeting offers the latest findings in your particular area of expertise. In addition, it offers unparalleled opportunities to hear and meet the researchers in other subdisciplines of the field who are making discoveries that will lead to your next advances. In short, the AACR Annual Meeting is a unique opportunity to explore every aspect of basic, clinical, and translational cancer research and to obtain the information and form the collaborations that are essential for both your current and future investigations.

To make it even easier for you to tap into this wealth of information and expertise, we have thoroughly revised the abstract submission categories. Please take the time to read through the expanded list of categories on Pages 8-10 before selecting a designation for your abstract; we think you will agree that they are more current and comprehensive. Furthermore, we expect this revision to improve the meeting in several important ways:

- Selection of an abstract category will be easier for those who, in the past, have been uncertain about the best category for their work or about the suitability of the AACR meeting for their presentations.
- The categories are presented in an order that we feel better reflects the actual problem of cancer, the path of recent progress in the field, and the likely synergies across subdisciplines. In choosing your specific abstract subclassification, you can more easily identify the appropriate major category (e.g., Molecular Biology, Clinical Investigations, Immunology) in which your work belongs.
- Abstracts are more likely to be reviewed and scheduled by the appropriate section of the Program Committee. We anticipate that the result will be more coherent and stimulating sessions of proffered papers.

Our goal in this First Announcement is to present this expanded abstract category list and to disseminate the necessary abstract forms to the scientific community as soon as possible. In about a month you will receive a Second Announcement that will again contain complete abstract submission information, but which will also contain

- preliminary information on the opening plenary session, symposia, "meet-the-expert" sunrise sessions, and controversy sessions.
- the advance registration form
- information on travel to and hotel accommodations in New Orleans
- employment register forms
- other important information on the meeting

The Program Committee recently completed an intensive meeting at which it selected topics for the major sessions of invited speakers. I am very excited about the sessions that are currently in development, and I urge you to look for the list in the Second Announcement and also to check the AACR Website periodically (http://www.aacr.org) for updates.

It is a privilege to serve you as Program Committee Chairperson at this exciting time in cancer research. Please join me in making the 89th Annual Meeting of the AACR the most important in the Association's history.

Very truly yours,

Frank J. Rauscher III, Ph.D.
Program Chairperson
Authors who submit an abstract of a paper for consideration for presentation at the Annual Meeting of the American Association for Cancer Research (AACR) confirm that they have not previously published these data, that they have not previously presented them at a national scientific meeting, and that they are not planning to present or publish them prior to the dates of the AACR Annual Meeting. AACR policy states that the content of submitted abstracts is kept strictly confidential by the members of the Program Committee during review and pre-publication processing. After review of the abstract by the Program Committee, the PRESENTER will be notified of its acceptance for presentation. The PRESENTER of the abstract must be one of the authors of the abstract, and it is expected that he or she will be the first author. Only those abstracts that are deemed acceptable for presentation by the Program Committee will be published in the Proceedings of the American Association for Cancer Research, which has a planned publication date of February 1998.

The paper presented at the annual meeting must coincide directly with the scientific content of the abstract submitted and reviewed by the Program Committee. If for any reason this is not possible, the paper must be withdrawn from presentation. Any requests for withdrawal of an abstract must be made in writing by the SPONSOR or PRESENTER. NOTE: Authors will be assessed a charge for any extraordinary production costs incurred as a result of the withdrawal of abstracts after the Proceedings issue is in press.

To provide a well-organized, effective scientific program the Program Committee will have full discretion to assign papers to minisymposia, poster discussion sessions, and poster sessions.

Minisymposia. Minisymposia will be planned from submitted abstracts. This format serves as a vehicle for the presentation and extensive discussion of developments in timely areas of cancer research.

Authors whose papers are assigned to minisymposia will be informed about the amount of time available for the delivery of their papers. At appropriate intervals, there will be opportunities for the discussion of each paper presented during the session. In addition, these sessions may include an invited talk to bring the subject into current perspective, an introduction, and a concluding discussion of the topic.

Poster Discussion Sessions. Poster discussion sessions will be scheduled from submitted abstracts and will run for four hours. The presentation of posters is supplemented by a focused discussion of the research areas under consideration. After presentation of the posters, there will be a one-hour discussion period led by two chairpersons with expertise in the area. Participants will have an opportunity to view the posters again after the discussion.

Prior to the annual meeting, the two chairpersons of these sessions will communicate directly with the authors presenting in the session to obtain more information on the work to be discussed. Authors will be expected to submit the content of their posters to the two chairpersons in advance of the meeting to make the ensuing discussion more effective.

Poster Sessions. Regular poster sessions will extend for four hours. Authors will be required to be present at their posters for the first three hours of the session. Detailed instructions for the preparation of posters will be sent to all authors whose abstracts are accepted for these sessions.

Late-Breaking Research Session. The firm deadline for submission of abstracts for publication in the Proceedings of the American Association for Cancer Research and for presentation at one of the regular sessions at the annual meeting is October 28, 1997. In addition, the AACR will provide an opportunity for the presentation of a few definitive reports of timely and highly significant research findings that become available after the October 28 abstract deadline. The work to be presented must be of major novelty and importance, e.g., the characterization of a new gene in familial cancer or the discovery of a new diagnostic marker. Complete instructions for submission of these abstracts will appear in a forthcoming AACR Annual Meeting announcement and in AACR journals in January 1998. The deadline for submission of abstracts for consideration for the Late-Breaking Research Session will be February 27, 1998.

Scheduling of Presentations. The AACR will do its utmost to assist any author who, for religious reasons, cannot present a paper on a particular day of the week. However, the complexities of scheduling thousands of papers for this multidisciplinary cancer research meeting require that sufficient notice from authors be given to the Program Committee. Authors who need special assistance with regard to the scheduling of their papers must enclose written requests along with their submitted abstracts.

SPONSORSHIP REGULATIONS

1. The SPONSOR must be a member of the Association in good standing. That is, an active, corresponding, or associate member must have paid his or her membership dues through 1997 by the time of the submission of the abstract in order to serve as the SPONSOR of one abstract for the upcoming annual meeting. As stated in the AACR By-Laws, honorary and emeritus members are exempt from the payment of dues; thus this regulation does not apply to them.

Special Limitations on Submissions by Associate Members. An associate member in good standing may SPONSOR his or her own abstract provided that (a) he or she is the PRESENTER of the abstract, and (b) an active or corresponding member in good standing also signs the abstract form ENDORsing the work. The ENDORSER does not thereby lose his or her own sponsorship privilege. NOTE: An associate member may SPONSOR only one abstract, and he or she must also be the PRESENTER of that abstract.

2. Each member of the AACR may SPONSOR only one abstract. There are no exceptions to this regulation. This privilege may be used in one of two ways: (a) the SPONSOR may be one of the authors of the abstract, or (b) the SPONSOR may sign the abstract form on behalf of the authors who may be either members or nonmembers of the AACR. (As noted above, however, an associate member may SPONSOR only an abstract that he or she PRESENTS.)

3. Each submitted abstract must carry the SPONSOR'S AACR Member Number. This number appears on the AACR
Membership Card and below the member’s name in the ACR Directory of Members. The SPONSOR must sign the abstract form.

4. A member or nonmember may be listed as a coauthor on more than one abstract, provided that each abstract has a different member SPONSOR.

5. The SPONSOR is obligated to ascertain that all authors are aware of the content of the abstract. Sponsorship of an abstract implies support for the data and the interpretations contained therein.

Please do not submit applications for active or corresponding membership along with your abstracts.

COMPLIANCE WITH THESE REGULATIONS IS THE RESPONSIBILITY OF THE SPONSOR. Adherence to these rules will be verified. Violations will result in the rejection and return of the abstract to the SPONSOR without consideration by the Program Committee.

INSTRUCTIONS FOR PREPARATION AND SUBMISSION OF ABSTRACTS

Each submitted abstract must carry the name, ACR Member Number, and signature of the SPONSOR on the appropriate lines of the abstract form. Each ACR member may sponsor only one abstract.

CONTENT OF ABSTRACTS

Authors who submit an abstract of a paper confirm that they have not previously published these data, that they have not previously presented them at a national scientific meeting, and that they are not planning to present or publish them prior to the dates of the ACR Annual Meeting.

Members of the Program Committee will evaluate the scientific quality of the submitted abstract on the basis of the following criteria: novelty of the research, significance of the findings, and clarity. Authors should be particularly cognizant of the importance of setting forth the objectives and hypotheses of the study in a clear, succinct manner and of summarizing the new, unpublished results. If the abstract is poorly written such that the Program Committee cannot determine its novelty and importance, the paper will not be accepted for presentation at the annual meeting.

1. Abstracts must describe in a succinct manner the purposes and results of the research so that the quality, originality, and comprehensiveness of the work can be evaluated by the Program Committee. Each abstract should contain: (a) an introductory sentence indicating the purposes of the study; (b) a brief description of pertinent experimental procedures; (c) a summary of the new, unpublished data; and (d) a statement of the conclusions. Authors must accept sole responsibility for the statements in their abstracts. Abstracts should be carefully proofread to avoid errors in the published literature.

2. Titles should be indicative of the content of the abstract. All words necessary to identify the subject matter should be included in the title to facilitate electronic retrieval (CD-ROM or online searches). Avoid nonstandard abbreviations in abstract titles.

3. Abbreviations may be used in the body of an abstract if they are defined at their first mention in the text. Complex therapeutic regimens must be identified.

4. NOTE: The ACR is committed to the advancement of cancer research and the cure of cancer through the facilitation of communication and dissemination of knowledge among scientists and others dedicated to the cancer problem. Therefore, the ACR requires strict compliance with the following regulations: When biological or chemical data pertaining to chemical entities are presented, the chemical structure, method of preparation, and patent or reference numbers must be provided. If for any reason this information cannot be presented at the meeting, the abstract on this work should not be submitted for consideration.

5. Because of administrative and time constraints, supplementary data submitted along with the abstract cannot be transmitted to the Program Committee for review.

GENERAL INSTRUCTIONS FOR SUBMISSION OF ABSTRACTS

The ACR will not accept abstracts for the 1998 Annual Meeting via Internet submission or by fax or e-mail delivery. Abstracts must be submitted on the official 1998 ACR abstract form. Two abstract forms are enclosed. Please pass one on to a colleague if you do not need it for your own use. The blank form may also be photocopied for use by others. Additional abstract forms may be obtained by calling or writing to the ACR Office. The blank form is also available as a PDF document that can be downloaded and printed from the ACR Website: <http://www.aacr.org/meeting.htm>. Instructions for completing the abstract form are given on the following pages.

To facilitate typesetting, authors are requested to send a floppy disk containing the abstract along with the required copies of the official abstract form. A list of acceptable word processing packages and detailed instructions for submitting the floppy disk are given on the following pages. The disk file must match the accompanying paper version of the abstract. If we discover any discrepancy, the paper copy will be considered the final version. If we cannot open or use your disk, or if you cannot supply a disk, we will typeset the abstract from the paper copy.

The accuracy of the submitted abstract is the responsibility of the authors. Every effort will be made to reproduce the abstract exactly as submitted on the abstract form. Errors made on your submitted abstract are therefore likely to appear in print. Careful preparation and proofreading prior to submission are essential. NOTE: ACR does not assume responsibility for errors in conversion of customized software, newly released software, or special characters.
A Temporary Abstract Number will be assigned to your abstract when it arrives at the AACR Office. This number will be listed on the card that is returned to you acknowledging receipt of your abstract. Please reference the Temporary Abstract Number in all subsequent communications with the AACR Office.

**ABSTRACT FORM**

The official abstract form must be completely filled out and signed in accordance with the instructions. Three (3) photocopies of the completed form must also be submitted. In addition to typing the abstract within the box according to the instructions given below, please provide the information and signatures requested on the abstract form and accompanying materials as follows. (NOTE: The numbered headings below correspond to the numbers on the abstract form.)

1. **Category and Subclassification.** Choose ONLY ONE category and subclassification. Indicate the category and subclassification in which your paper belongs by typing the appropriate five-character code in the blocks provided. A list of codes for the categories and subclassifications appears on Pages 8-10 of this booklet. The list is also available at the AACR Website. These designations will serve as a guide to the Program Committee in the grouping of abstracts but will not necessarily be the actual titles of scientific sessions to be held at the annual meeting.

2. **Sponsor of the Abstract.** Type the AACR member number, name, address, telephone and FAX numbers, and e-mail address of the member using his or her membership privilege to SPONSOR the abstract. (Member numbers can be found on an individual's membership card and in the AACR Directory of Members.) The SPONSOR, who must be a member of the AACR in good standing through 1997, may SPONSOR only one abstract. (See Page 3 for Sponsorship Regulations.)

3. **Sponsor Signature.** The SPONSOR must sign the form in the space provided to indicate support for the data and interpretations contained in the abstract.

4. **Associate Members Only.** If an associate member is the SPONSOR AND PRESENTER of the abstract, he or she must ask an active or corresponding member in good standing or an emeritus or honorary member to sign Line 4 of the form as an ENDORSEMENT of the work. Type the name and member number of the ENDORSING member on the appropriate lines.

5. **Eligibility for Young Investigator Awards for American and International Scientists.**

A. The AACR is very grateful to the growing number of sponsors who help several hundred young investigators attend the annual meeting each year. Starting in 1998, ITO EN, Ltd. is underwriting a major enhancement of the AACR’s program of travel grants for both American and International Scientists, i.e., an expanded number of awards for young investigators from Asia. ITO EN has already made a commitment to continue its very generous support of this new program through 2002.

   **Submission of an abstract by the deadline of October 28 is an absolute prerequisite for receipt of any AACR travel award.** Qualified scientists from all countries are therefore encouraged to submit abstracts and to indicate their eligibility for these awards by observing the following instructions: Indicate whether the PRESENTER of the abstract is a medical student, graduate student, physician in training, or postdoctoral fellow from an academic or governmental organization. PRESENTERS who meet these requirements and who are first authors on abstracts given high ratings by the Program Committee for scientific merit may be candidates for a young investigator award. If a PRESENTER is eligible based on the above criteria and is under consideration, a letter confirming his or her status, submitted on the official letterhead of the PRESENTER’s institution and signed by the registrar, dean, or department head of that institution, will be requested at a later date.

B. Minority Scholar Awards in Cancer Research are available if the PRESENTER meets the above-mentioned criteria and is African American, Hispanic, American Indian, Native Alaskan, or Native Pacific Islander. Through a generous grant provided by the Comprehensive Minority Biomedical Program of the National Cancer Institute, funds are available to encourage participation in the annual meeting by minority groups which have been traditionally underrepresented in cancer and biomedical research. Eligible scientists are young, full-time predoctoral (graduate or medical) students, postdoctoral fellows, and physicians in training who are either engaged in cancer research, or who have training that could lead to contributions in this field. Only citizens of the United States and Canada or scientists who are permanent residents in those countries may receive one of these awards.

   Although preference will be shown to authors of abstracts that have been accepted for presentation at the 1998 AACR Annual Meeting, this is not a requirement for the award. Awardees will be selected on the basis of their qualifications, references from mentors, and an estimation of the potential professional benefit to the awardees. An advisory committee consisting of members of the AACR carefully reviews submitted applications and letters of reference. The award will consist of partial support for the registration, travel, and subsistence expenses incurred in connection with attendance at the annual meeting.

   Persons checking this box will receive an application form which must be completed and returned to the AACR by December 1, 1997. Applicants will be chosen from both minority institutions and the larger bodies of universities, colleges, and research institutes. If accepted, applicants are expected to attend at least three full days of scientific sessions at the annual meeting and participate in all planned activities for the awardees. They are also required to submit a report commenting on the scientific sessions they attended at the annual meeting and the Minority Scholar Program.

6. **Presenter of Abstract.** Type the name, AACR member number (if applicable), address, telephone and FAX numbers, and e-mail address of the PRESENTER of the paper in the space provided. The PRESENTER must be one of the authors of the abstract. It is generally expected that the first author of an abstract will be its PRESENTER.

7. **Presenter Signature.** The PRESENTER of the paper must sign the form in the space provided to acknowledge that the Copyright Transfer/Conflict of Interest Disclosure Form has been completed, and to give the AACR permission to arrange for audiotape recording and the subsequent sale of audiotape cassettes of the papers delivered orally at the 1998 AACR Annual Meeting. Your advance permission for taping in the event that your paper is among those to be recorded is appreciated.

8. **Payment of US$40 Abstract Submission Fee.** Please indicate your method of payment. Remember to list the name of the PRESENTER on your enclosed check. If you want the Abstract Submission Fee (US$40) to be billed to your credit card, please fill in the necessary information and sign in the space provided. Purchase orders cannot be accepted.

---

Please check all the information you have entered for correctness and adherence to AACR submission rules. Infractions of sponsorship regulations will result in the rejection and return of the abstract to the SPONSOR without consideration by the Program Committee. Infractions of format, including forms submitted without the required signatures, will result in an additional fee of US$40, which will be billed to the SPONSOR.
FORMAT OF ABSTRACTS

Abstracts will be reproduced for publication either by typesetting from the paper copy of the abstract form or, if possible, by using the floppy disk provided by the author (see below for instructions on supplying a floppy disk). We will not accept disks that are unaccompanied by the required paper copies of the official abstract form. The disk file must match the accompanying paper version of the abstract. If we discover any discrepancy, the paper copy will be considered the final version.

The accuracy of the submitted abstract is the responsibility of the authors. Every effort will be made to reproduce the abstract exactly as submitted on the abstract form. Errors made on your submitted abstract are therefore likely to appear in print. Careful preparation and proofreading are essential prior to submission. NOTE: AACR does not assume responsibility for errors in conversion of customized software, newly released software, or special characters.

Only abstracts submitted on the official 1998 abstract form will be considered by the Program Committee. Before typing the abstract on the form, read all instructions and examine the sample abstract thoroughly. Prepare your abstract in accordance with the approved format shown in the sample abstract (Page 12). Please note in particular the following regulations concerning format:

Dimensions: The entire abstract, including text, title, authors, and affiliations, must fit within the box provided on the abstract form. The dimensions of the box are 5 inches (12.5 cm) wide x 4 inches (10 cm) high. Do not reduce the abstract mechanically to fit into the box. Type the abstract single spaced.

Type: Abstracts may be printed using laser or ink-jet printers with type no smaller than 10-point. Abstracts may also be prepared using typewriters or daisy-wheel printers with a sharp black ribbon and a printing element no smaller than 12-pitch (elite). Do not use dot matrix printers. Symbols and special characters should not be created graphically. Instead, use the character set provided in your word processor. Any symbols that must be drawn by hand should be drawn with black ink.

Title: Use boldface type for the title if possible. The first line of the title should be flush with the left margin of the abstract box. Capitalize only the first letter of the first word; type the rest in lower case except where lower case is incorrect, e.g., “DNA.” Avoid nonstandard abbreviations in the title. (See Cancer Research Instructions for Authors, Vol. 57: 186-192, 1997, for a list of standard abbreviations.) Type a period at the end of the title.

Authors’ Names: Type the authors’ names as a group. For each author, type surname first followed by given name and initials. Omit academic degrees. Do not use footnote numbers or symbols after the authors’ names to refer to their individual affiliations. See next paragraph.

Affiliations: List affiliations as a group at the end of the list of authors’ names. For each affiliation, type the name of the institution, city, state in abbreviated form, zip code, and country. We prefer that you do not key the affiliation of each author to his/her name. However, if you are obligated to do so, do not use footnote numbers or symbols after an author’s name to refer to his/her affiliation. Instead, put the author’s initials in parentheses at the end of his/her affiliation.

Text: Begin the text on a separate line after the affiliations, flush with the left margin of the abstract box. Type the text single spaced in one paragraph. Nonstandard abbreviations are permitted in the text of the abstract if they appear in parentheses immediately after the term being abbreviated at the first usage of that term in the text. TABLES, CHARTS, ILLUSTRATIONS, HALFTONES, AND COLOR PHOTOGRAPHS ARE NOT ACCEPTABLE AS PART OF YOUR ABSTRACT AND SHOULD NOT BE SUBMITTED.

SUBMITTING A COPY OF THE ABSTRACT ON FLOPPY DISK

To facilitate typesetting, authors are requested to send a floppy disk containing the abstract along with the required copies of the official abstract form.

SUBMIT ONLY ONE ABSTRACT PER DISK!

Only one abstract per disk will be handled as a submission; any others on that disk will be ignored.

The following is a list of acceptable word processing packages in which to prepare the disk file of the abstract. Please do not convert your file to one of these formats from other word processors; instead, create your file in one of these programs:

Macintosh: MS Word 4.0, 5.0-5.1, 6.0
          WordPerfect 1.0, 2.0, 3.0
          MacWrite Pro
          Rich Text Format

Windows: MS Word 2.0, 6.0, 7.0, '97
          WordPerfect 5.0-5.2, 6.0, 7.0
          XyWrite

DOS: MS Word 5.0
     WordPerfect 4.2, 5.0-5.2, 6.0
     Rich Text Format
     XyWrite

The disk file must match the accompanying paper version of the abstract. If we discover any discrepancy, the paper copy will be considered the final version. If we cannot open or use your disk, or if you cannot supply a disk, we will typeset the abstract from the paper copy. We will not use a disk if we receive it separately from the paper submission of the abstract form.

The accuracy of the submitted abstract is the responsibility of the authors. Every effort will be made to reproduce the abstract exactly as submitted on the abstract form. Errors made on your submitted abstract are therefore likely to appear in print. Careful preparation and proofreading prior to submission are essential. NOTE: AACR does not assume responsibility for errors in conversion of customized software, newly released software, or special characters.

The abstract on disk must meet all the format requirements specified for paper abstract submissions and must fit within the size limits delineated on the abstract form; that is, able to fit within a space 5 inches (12.5 cm) wide x 4 inches (10 cm) high, single-spaced, in 10-point type. Symbols and special characters should not be created graphically. Instead, use the character set provided in your word processor. TABLES, CHARTS, ILLUSTRATIONS, HALFTONES, AND COLOR PHOTOGRAPHS ARE NOT ACCEPTABLE AS PART OF YOUR ABSTRACT AND SHOULD NOT BE SUBMITTED.

Type or print the following information on the outer label of the disk:

| abstract title |
| name of the first author |
| name of the disk file |
| model of the computer used (e.g., IBM/PS2) |
| operating system/version (e.g., DOS 3.3) |
| word processing program/version (e.g., WordPerfect 5.0) |

Insert the disk into a disk mailer or other protective envelope. Clip the disk mailer to the paper copies of the abstract, and enclose them with all the other materials required for abstract submission.
INSTRUCTIONS FOR COMPLETING THE COPYRIGHT TRANSFER/CONFLICT OF INTEREST DISCLOSURE FORM

All PRESENTERS must submit the signed original plus one copy of this completed form along with their abstracts.

Copyright Transfer. The PRESENTER of the paper, as an author of the abstract and on behalf of all the authors, must check the appropriate box and sign this section of the form.

Conflict of Interest Disclosure. The Tulane University School of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to sponsor continuing medical education for physicians. The ACCME has applied to Tulane for accreditation of the Annual Meeting as an educational activity for Category 1 credits towards the Physician's Recognition Award Program of the American Medical Association. The ACCME requires that all PRESENTERS at accredited activities declare whether they have any financial or other interest which might be construed as resulting in an actual, potential, or apparent conflict of interest in the work presented. The ACCME Board of Directors has accepted this principle and has made such a declaration a prerequisite of abstract submission. The existence of financial interests or other relationships of a commercial nature are not regarded by the ACCME as creating a presumption of impropriety. Rather, the ACCME desires to make as much relevant information available as possible to those reviewing the data being presented.

All PRESENTERS, whether or not they have a financial or other interest in the work they intend to present, must complete and sign the Conflict of Interest Disclosure section of the form on Page 11 of this booklet. The form may also be downloaded as a PDF file from the ACCME's Website. Failure to submit this form along with an abstract form by October 28, 1997, will result in return of the abstract to the PRESENTER without consideration by the Program Committee.

MAILING INSTRUCTIONS

1. Abstracts must be received in the office of the American Association for Cancer Research no later than October 28, 1997. Submission at an earlier date would be appreciated. The AACR urges investigators working outside of the United States to send their abstracts well ahead of the deadline date or to use one of the international courier services that offer delivery within a few days. The deadline for receipt must be applied uniformly to all abstracts regardless of their origin. FAX or other electronic transmittals will not be accepted.

2. Enclose the following materials unfolded and with cardboard backing in an envelope of suitable size:
   A. An original plus three (3) legible copies of the completed abstract form signed by the SPONSOR and PRESENTER.
   B. If available, a copy of the abstract on floppy disk. See instructions above for preparing and labeling the disk. Insert your disk into a disk mailer or other protective envelope and clip it to the paper copies of the abstract.
   C. A check for US$40 payable to the American Association for Cancer Research, Inc. All checks must be drawn on United States banks. PLEASE LIST THE NAME OF THE PRESENTER ON YOUR CHECK. If you wish us to charge this amount to your credit card, fill out and sign Item 8 on the abstract form. Purchase orders are not acceptable for payment of the abstract submission fee.

D. The completed and signed Copyright Transfer/Conflict of Interest Disclosure Form plus one photocopy.

E. The Acknowledgment Card attached to this announcement. The names of the authors and the title of the paper should be filled in on the card prior to submission. The card will be returned to you showing the Temporary Abstract Number assigned to your abstract. This number should be referenced in all correspondence or telephone calls to the AACR Office. PRESENTER: To ensure receipt of the Acknowledgment Card, put your own address on the reverse of the card and affix proper postage.

F. One stamped, regular letter-sized envelope (about 4 x 9 1/2 inches, 10.2 x 24.2 cm) addressed to the PRESENTER. The final decision of the Program Committee concerning acceptability for presentation and publication will be returned in this envelope along with any other necessary instructions.

3. Send the materials listed above together in one envelope to:
   American Association for Cancer Research, Inc.
   1998 ANNUAL MEETING ABSTRACT
   Public Ledger Building, Suite 826
   150 S. Independence Mall West
   Philadelphia, PA 19106-3483

4. Do not enclose membership application forms, membership dues, advance registration forms, housing forms, or any other materials in the envelope with your abstract submission.

Special mailing charges cannot be paid by the AACR. The AACR staff cannot assume responsibility for abstracts that are not delivered directly to the premises.

SUBMISSION OF CORRECTED ABSTRACTS

If after submitting your abstract you discover an error, please do not submit a corrected abstract until you have received an acknowledgment card containing the Temporary Abstract Number of your original submission. You may then submit a corrected abstract in strict accordance with the following instructions:

1. On a photocopy of the original abstract, indicate the correction(s) you are making.

2. On an official abstract form in the box provided, type the full text of the resubmitted abstract prepared according to the Format instructions above. Answer all the questions on the form. If possible, supply a file of the resubmitted version on floppy disk. (See instructions for disk submission above.)

3. Label both the original and resubmitted abstract forms in the upper right hand corner with your Temporary Abstract Number and the word “Resubmission.” Put this information on the outer label of your resubmitted disk as well.

4. Send the corrected original abstract, an original and three copies of the resubmitted abstract on the official form, and your resubmitted disk to the address given on the next page. Write or type the word “Resubmission” on the mailing envelope.

Authors will be charged for any extraordinary production costs incurred as a result of abstracts being resubmitted or withdrawn after the Proceedings is in production. The AACR will not be responsible for the acceptance and processing of corrected abstracts that are not submitted in compliance with the above regulations. No substantive changes may be made in abstracts after they have undergone scientific review, and the AACR cannot accept any resubmission or comply with any request for withdrawal of an abstract that will delay the publication of the Proceedings.

THE OCTOBER 28, 1997, DEADLINE WILL BE STRICTLY ENFORCED.
<table>
<thead>
<tr>
<th>BL</th>
<th>CELL AND TUMOR BIOLOGY</th>
</tr>
</thead>
<tbody>
<tr>
<td>BL1</td>
<td>Cell Growth Signaling Pathways: Cell Biology Aspects</td>
</tr>
<tr>
<td>BL1-01</td>
<td>Growth factors: structure and function</td>
</tr>
<tr>
<td>BL1-02</td>
<td>Receptors: structure and function</td>
</tr>
<tr>
<td>BL1-03</td>
<td>Signaling: membrane to nucleus</td>
</tr>
<tr>
<td>BL1-04</td>
<td>Autocrine-paracrine signaling</td>
</tr>
<tr>
<td>BL1-05</td>
<td>Physiology/organismal homeostasis</td>
</tr>
<tr>
<td>BL1-06</td>
<td>Cell-matrix interactions</td>
</tr>
<tr>
<td>BL1-07</td>
<td>Adhesion and cytoarchitecture inputs</td>
</tr>
<tr>
<td>BL1-08</td>
<td>Cell-cell interactions: communication/ GAP junctions</td>
</tr>
<tr>
<td>BL1-09</td>
<td>Cell-cell adhesion receptors</td>
</tr>
<tr>
<td>BL1-10</td>
<td>Tumor-stromal cell interactions</td>
</tr>
<tr>
<td>BL1-11</td>
<td>Organogenesis and tumor development</td>
</tr>
<tr>
<td>BL1-12</td>
<td>Cell and tissue kinetics/physiology</td>
</tr>
<tr>
<td>BL1-13</td>
<td>Tissue remodeling and regeneration</td>
</tr>
<tr>
<td>BL1-14</td>
<td>Wound healing and tissue repair</td>
</tr>
<tr>
<td>BL1-15</td>
<td>Animal models of tissue host-tumor interactions</td>
</tr>
<tr>
<td>BL1-16</td>
<td>Other</td>
</tr>
<tr>
<td>BL2</td>
<td>Cell Death Signaling</td>
</tr>
<tr>
<td>BL2-01</td>
<td>Transcriptional control of apoptosis</td>
</tr>
<tr>
<td>BL2-02</td>
<td>Genetic and developmental controls</td>
</tr>
<tr>
<td>BL2-03</td>
<td>Receptor coupled signaling to apoptosis</td>
</tr>
<tr>
<td>BL2-04</td>
<td>Death protein networks</td>
</tr>
<tr>
<td>BL2-05</td>
<td>ICE proteases/caspases: cascades: substrates</td>
</tr>
<tr>
<td>BL2-06</td>
<td>Caspase inhibitors: experimental and preclinical</td>
</tr>
<tr>
<td>BL2-07</td>
<td>Enzymology of apoptosis</td>
</tr>
<tr>
<td>BL2-08</td>
<td>Nuclear targets/effectors of apoptosis</td>
</tr>
<tr>
<td>BL2-09</td>
<td>Growth factors and other survival signals</td>
</tr>
<tr>
<td>BL2-10</td>
<td>Cell adhesion/cell-cell interactions in apoptosis</td>
</tr>
<tr>
<td>BL2-11</td>
<td>Developmental control of apoptosis: organ sites</td>
</tr>
<tr>
<td>BL2-12</td>
<td>Hematopoiesis</td>
</tr>
<tr>
<td>BL2-13</td>
<td>Lymphopoiesis</td>
</tr>
<tr>
<td>BL2-14</td>
<td>Breast: development/lactation/ regression</td>
</tr>
<tr>
<td>BL2-15</td>
<td>Prostate</td>
</tr>
<tr>
<td>BL2-16</td>
<td>Other</td>
</tr>
<tr>
<td>BL2-17</td>
<td>Bcl-2 pathways: effectors and inhibitors</td>
</tr>
<tr>
<td>BL2-18</td>
<td>Bax, TNF receptor family</td>
</tr>
<tr>
<td>BL3</td>
<td>Tumor Progression, Invasion, and Metastasis</td>
</tr>
<tr>
<td>BL3-01</td>
<td>Tissue degradation: proteases-inhibitor systems</td>
</tr>
<tr>
<td>BL3-02</td>
<td>Modility: receptors and signaling</td>
</tr>
<tr>
<td>BL3-03</td>
<td>Adhesion-extravasation-migration</td>
</tr>
<tr>
<td>BL3-04</td>
<td>Inflammation and tumor development</td>
</tr>
<tr>
<td>BL3-05</td>
<td>Macrophage-tumor interactions</td>
</tr>
<tr>
<td>BL3-06</td>
<td>Organ-specific metastasis</td>
</tr>
<tr>
<td>BL3-07</td>
<td>New metastasis genes</td>
</tr>
<tr>
<td>BL3-08</td>
<td>Mechanisms of cell motility and migration</td>
</tr>
<tr>
<td>BL3-09</td>
<td>Mechanisms of bone metastasis</td>
</tr>
<tr>
<td>BL3-10</td>
<td>Xenograft-metastasis systems and their models</td>
</tr>
<tr>
<td>BL3-11</td>
<td>Occult metastasis: detection</td>
</tr>
<tr>
<td>BL3-12</td>
<td>Other</td>
</tr>
<tr>
<td>BL4</td>
<td>Host-Tumor Interactions: Angiogenesis and Microcirculation</td>
</tr>
<tr>
<td>BL4-01</td>
<td>Mechanisms and signaling events</td>
</tr>
<tr>
<td>BL4-02</td>
<td>Angiogenic factors and receptors</td>
</tr>
<tr>
<td>BL4-03</td>
<td>Angiogenesis inhibitors: endogenous and synthetic</td>
</tr>
<tr>
<td>BL4-04</td>
<td>Endothelial cell functions</td>
</tr>
<tr>
<td>BL4-05</td>
<td>Blood flow and microcirculation</td>
</tr>
<tr>
<td>BL4-06</td>
<td>Vascular, lymphatic, and interstitial transport</td>
</tr>
<tr>
<td>BL4-07</td>
<td>Physiological resistance to cancer therapy</td>
</tr>
<tr>
<td>BL4-08</td>
<td>Vascular structural reorganization</td>
</tr>
<tr>
<td>BL4-09</td>
<td>Other</td>
</tr>
<tr>
<td>MB</td>
<td>MOLECULAR BIOLOGY</td>
</tr>
<tr>
<td>MB1</td>
<td>Cancer Genetics I: New Loci and Mechanisms of Genomic Alterations</td>
</tr>
<tr>
<td>MB1-01</td>
<td>New human cancer genes: mapping of loci and cloning</td>
</tr>
<tr>
<td>MB1-02</td>
<td>Molecular cytogenetics</td>
</tr>
<tr>
<td>MB1-03</td>
<td>Comparative genomic hybridization</td>
</tr>
<tr>
<td>MB1-04</td>
<td>LOH and marker studies</td>
</tr>
<tr>
<td>MB1-05</td>
<td>Familial cancer and linkage studies</td>
</tr>
<tr>
<td>MB1-06</td>
<td>Positional cloning</td>
</tr>
<tr>
<td>MB1-07</td>
<td>Expression cloning strategies</td>
</tr>
<tr>
<td>MB1-08</td>
<td>New mutation detection methods</td>
</tr>
<tr>
<td>MB1-09</td>
<td>Mechanisms of genomic alterations</td>
</tr>
<tr>
<td>MB2</td>
<td>Cancer Genetics II: Tumor Suppressor Genes: Structure and Function</td>
</tr>
<tr>
<td>MB2-01</td>
<td>New mutations in human tumors</td>
</tr>
<tr>
<td>MB2-02</td>
<td>Genotype/phenotype correlations</td>
</tr>
<tr>
<td>MB2-03</td>
<td>New functional aspects of selected known tumor suppressor genes</td>
</tr>
<tr>
<td>MB2-04</td>
<td>p53</td>
</tr>
<tr>
<td>MB2-05</td>
<td>Rb and family</td>
</tr>
<tr>
<td>MB2-06</td>
<td>WT1</td>
</tr>
<tr>
<td>MB2-07</td>
<td>NF1/NF2</td>
</tr>
<tr>
<td>MB2-08</td>
<td>VHL</td>
</tr>
<tr>
<td>MB2-09</td>
<td>DCC</td>
</tr>
<tr>
<td>MB2-10</td>
<td>APC</td>
</tr>
<tr>
<td>MB2-11</td>
<td>BRCA1</td>
</tr>
<tr>
<td>MB2-12</td>
<td>Other</td>
</tr>
<tr>
<td>MB2-13</td>
<td>New tumor suppressor genes</td>
</tr>
<tr>
<td>MB2-14</td>
<td>Suppressors of metastasis</td>
</tr>
<tr>
<td>MB2-15</td>
<td>Tumor suppressor networks - functional pathways</td>
</tr>
<tr>
<td>MB2-16</td>
<td>Other</td>
</tr>
<tr>
<td>MB3</td>
<td>Cancer Genetics III: Human and Retroviral Oncogenes: Structure and Function</td>
</tr>
<tr>
<td>MB3-01</td>
<td>Growth factors and soluble molecules</td>
</tr>
<tr>
<td>MB3-02</td>
<td>Protein tyrosine kinase: receptor and nonreceptor</td>
</tr>
<tr>
<td>MB3-03</td>
<td>Protein serine-threonine kinases: receptor and nonreceptor</td>
</tr>
<tr>
<td>MB3-04</td>
<td>Phosphatases: receptor and nonreceptor</td>
</tr>
<tr>
<td>MB3-05</td>
<td>Cystolic adaptors and intermediate molecules</td>
</tr>
<tr>
<td>MB3-06</td>
<td>Guanine nucleotide binding proteins and effectors</td>
</tr>
<tr>
<td>MB3-07</td>
<td>Mitogen-activated kinase cascades</td>
</tr>
<tr>
<td>MB3-08</td>
<td>Oncogenic transcription factors</td>
</tr>
<tr>
<td>MB3-09</td>
<td>New onecogenes</td>
</tr>
<tr>
<td>MB3-10</td>
<td>New onecogene networks</td>
</tr>
<tr>
<td>MB3-11</td>
<td>Other</td>
</tr>
<tr>
<td>MB4</td>
<td>Gene Expression and Epigenetic Regulation</td>
</tr>
<tr>
<td>MB4-01</td>
<td>Cancer genome anatomy: comparative expression patterns</td>
</tr>
<tr>
<td>MB4-02</td>
<td>New methods in tumor microdissection/comparative expression</td>
</tr>
<tr>
<td>MB4-03</td>
<td>DNA methylation and maintenance</td>
</tr>
<tr>
<td>MB4-04</td>
<td>Enzymology of DNA methylation/ modification</td>
</tr>
<tr>
<td>MB4-05</td>
<td>Imprinting and allele-specific expression</td>
</tr>
<tr>
<td>MB4-06</td>
<td>Silencing and reactivation of gene expression</td>
</tr>
<tr>
<td>MB4-07</td>
<td>Telomeres and telomerase</td>
</tr>
<tr>
<td>MB4-08</td>
<td>Cellular aging and senescence: molecular studies</td>
</tr>
<tr>
<td>MB4-09</td>
<td>Other</td>
</tr>
<tr>
<td>MB5</td>
<td>Gene Regulation and Transcriptional Control of the Cancer Phenotype</td>
</tr>
<tr>
<td>MB5-01</td>
<td>Basic mechanisms of transcription: biochemistry/epigenology</td>
</tr>
<tr>
<td>MB5-02</td>
<td>Transcription-coupled repair: genetics/biochemistry</td>
</tr>
<tr>
<td>MB5-03</td>
<td>Promoter/enhancer analysis</td>
</tr>
<tr>
<td>MB5-04</td>
<td>Growth factor-inducible gene expression</td>
</tr>
<tr>
<td>MB5-05</td>
<td>Oncogenic transcription factor: leukemias/lymphomas/solid tumors</td>
</tr>
<tr>
<td>MB5-06</td>
<td>Transgenic models of promoter and transcription factor function</td>
</tr>
<tr>
<td>MB5-07</td>
<td>Protein-protein interaction in transcription factor function</td>
</tr>
<tr>
<td>MB5-08</td>
<td>Protein phosphorylation and control of gene expression</td>
</tr>
<tr>
<td>MB5-09</td>
<td>Transcriptional control of cell differentiation</td>
</tr>
<tr>
<td>MB5-10</td>
<td>Transcriptional programs and organogenesis</td>
</tr>
<tr>
<td>MB5-11</td>
<td>Chromatin structure/higher order regulation</td>
</tr>
<tr>
<td>MB5-12</td>
<td>Gene position effects and genomic sensing</td>
</tr>
<tr>
<td>MB5-13</td>
<td>Anti-sense control of gene expression</td>
</tr>
<tr>
<td>MB5-14</td>
<td>Posttranscriptional and translational control</td>
</tr>
<tr>
<td>MB5-15</td>
<td>New methods for multiplex analysis of gene expression</td>
</tr>
<tr>
<td>MB5-16</td>
<td>Structural biology of transcription factors</td>
</tr>
<tr>
<td>MB5-17</td>
<td>Other</td>
</tr>
<tr>
<td>MB6</td>
<td>Cell Cycle</td>
</tr>
<tr>
<td>MB6-01</td>
<td>Growth factor control of cell cycle</td>
</tr>
<tr>
<td>MB6-02</td>
<td>Genetic control of cell cycle progression</td>
</tr>
<tr>
<td>MB6-03</td>
<td>Cell cycle genetic alterations</td>
</tr>
<tr>
<td>MB6-04</td>
<td>Cell cycle checkpoints</td>
</tr>
<tr>
<td>MB6-05</td>
<td>Checkpoints: genetics and biochemistry</td>
</tr>
<tr>
<td>MB6-06</td>
<td>Cyclins and CDKs</td>
</tr>
<tr>
<td>MB6-07</td>
<td>CDK inhibitors</td>
</tr>
<tr>
<td>MB6-08</td>
<td>Phosphorylation and proteolysis in cell cycle control</td>
</tr>
<tr>
<td>MB6-09</td>
<td>Negative regulation of cell cycle</td>
</tr>
<tr>
<td>MB6-10</td>
<td>Viral oncoproteins and cell cycle regulation</td>
</tr>
<tr>
<td>MB6-11</td>
<td>Other</td>
</tr>
<tr>
<td>MB7</td>
<td>Viral Oncogenesis</td>
</tr>
<tr>
<td>-----</td>
<td>-----------------------------------</td>
</tr>
<tr>
<td>MB7-01</td>
<td>Viruses and susceptibility/promotion</td>
</tr>
<tr>
<td>MB7-02</td>
<td>Human tumor viruses: etiology/epidemiology</td>
</tr>
<tr>
<td>MB7-03</td>
<td>Molecular biology and genetics of viruses</td>
</tr>
<tr>
<td>MB7-04</td>
<td>DNA tumor viruses</td>
</tr>
<tr>
<td>MB7-05</td>
<td>Viral transformation and carcinogenesis</td>
</tr>
<tr>
<td>MB7-06</td>
<td>Viral gene regulation</td>
</tr>
<tr>
<td>MB7-07</td>
<td>Viral onco genes</td>
</tr>
<tr>
<td>MB7-08</td>
<td>Host-virus interactions</td>
</tr>
<tr>
<td>MB7-09</td>
<td>Other</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>CG</th>
<th>CARCINOGENESIS</th>
</tr>
</thead>
<tbody>
<tr>
<td>CG1</td>
<td>Biomarkers, Premalignant Lesions, Risk Assessment</td>
</tr>
<tr>
<td>CG1-01</td>
<td>Biomarkers of exposure to carcinogens</td>
</tr>
<tr>
<td>CG1-02</td>
<td>Environmental carcinogenesis</td>
</tr>
<tr>
<td>CG1-03</td>
<td>Carcinogenesis in fish models</td>
</tr>
<tr>
<td>CG1-04</td>
<td>Genetic susceptibility and risk assessment</td>
</tr>
<tr>
<td>CG1-05</td>
<td>Predictive assays for carcinogenicity</td>
</tr>
<tr>
<td>CG1-06</td>
<td>Premalignant lesions</td>
</tr>
<tr>
<td>CG1-07</td>
<td>Toxicology and carcinogenesis</td>
</tr>
<tr>
<td>CG1-08</td>
<td>Drug metabolizing enzymes</td>
</tr>
<tr>
<td>CG1-09</td>
<td>GST/GST</td>
</tr>
<tr>
<td>CG1-10</td>
<td>Other</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>CG2</th>
<th>Molecular Carcinogenesis: Metabolism, DNA Lesions, Mutagenesis, and Repair</th>
</tr>
</thead>
<tbody>
<tr>
<td>CG2-01</td>
<td>Biochemical aspects of carcinogen function: enzymatic bioactivation</td>
</tr>
<tr>
<td>CG2-02</td>
<td>Biochemistry of DNA repair</td>
</tr>
<tr>
<td>CG2-03</td>
<td>DNA adducts: identification and conformational effects</td>
</tr>
<tr>
<td>CG2-04</td>
<td>DNA adducts: repair and sequence specificity</td>
</tr>
<tr>
<td>CG2-05</td>
<td>Genetic and cytogenetic alterations</td>
</tr>
<tr>
<td>CG2-06</td>
<td>Metabolism and activation of carcinogens in animal models and humans</td>
</tr>
<tr>
<td>CG2-07</td>
<td>Molecular responses to DNA damage</td>
</tr>
<tr>
<td>CG2-08</td>
<td>Mutagenesis</td>
</tr>
<tr>
<td>CG2-09</td>
<td>Mutational spectrum of carcinogens</td>
</tr>
<tr>
<td>CG2-10</td>
<td>Oxygen radicals</td>
</tr>
<tr>
<td>CG2-11</td>
<td>Other</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>CG3</th>
<th>Promotion and Progression</th>
</tr>
</thead>
<tbody>
<tr>
<td>CG3-01</td>
<td>Cellular transformation</td>
</tr>
<tr>
<td>CG3-02</td>
<td>Growth factors in progression</td>
</tr>
<tr>
<td>CG3-03</td>
<td>Mesenchymal/epithelial interactions</td>
</tr>
<tr>
<td>CG3-04</td>
<td>Signal transduction</td>
</tr>
<tr>
<td>CG3-05</td>
<td>Tumor promotion and progression</td>
</tr>
<tr>
<td>CG3-06</td>
<td>Other</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>EP</th>
<th>EPIDEMIOLOGY</th>
</tr>
</thead>
<tbody>
<tr>
<td>EP1</td>
<td>Analytical Epidemiology in Populations</td>
</tr>
<tr>
<td>EP1-01</td>
<td>Behavioral epidemiology</td>
</tr>
<tr>
<td>EP1-02</td>
<td>Cancer in minority and medically underserved populations</td>
</tr>
<tr>
<td>EP1-03</td>
<td>Diet, nutrition, and lifestyle factors</td>
</tr>
<tr>
<td>EP1-04</td>
<td>Environmental and occupational etiology</td>
</tr>
<tr>
<td>EP1-05</td>
<td>Radiation exposure and cancer risk</td>
</tr>
<tr>
<td>EP1-06</td>
<td>Gene-environment interactions</td>
</tr>
<tr>
<td>EP1-07</td>
<td>Human tumor viruses and other infectious agents in susceptible populations</td>
</tr>
<tr>
<td>EP1-08</td>
<td>Genetic polymorphisms and metabolizing enzymes</td>
</tr>
<tr>
<td>EP1-09</td>
<td>Preneoplastic lesions</td>
</tr>
<tr>
<td>EP1-10</td>
<td>Methodology, computer modeling, and biostatistics</td>
</tr>
<tr>
<td>EP1-11</td>
<td>Other</td>
</tr>
<tr>
<td>EP2</td>
<td>Genetic and Molecular Epidemiology</td>
</tr>
<tr>
<td>EP2-01</td>
<td>Genetic markers and biomarkers in epidemiology</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>PR</th>
<th>PREVENTION</th>
</tr>
</thead>
<tbody>
<tr>
<td>PR1</td>
<td>Preclinical Prevention Studies: Markers and Mechanisms</td>
</tr>
<tr>
<td>PR1-01</td>
<td>Animal/transgenic models in promotion and prevention</td>
</tr>
<tr>
<td>PR1-02</td>
<td>Biological and biochemical mechanisms in prevention</td>
</tr>
<tr>
<td>PR1-03</td>
<td>Biomarkers and intervention studies</td>
</tr>
<tr>
<td>PR1-04</td>
<td>Molecular markers in prevention research</td>
</tr>
<tr>
<td>PR1-05</td>
<td>Caloric restriction</td>
</tr>
<tr>
<td>PR1-06</td>
<td>Cellular models in prevention research</td>
</tr>
<tr>
<td>PR1-07</td>
<td>Chemoprevention</td>
</tr>
<tr>
<td>PR1-08</td>
<td>Diet, nutrition, and cancer</td>
</tr>
<tr>
<td>PR1-09</td>
<td>Genetic influences on diet and cancer</td>
</tr>
<tr>
<td>PR1-10</td>
<td>Genetic susceptibility and prevention</td>
</tr>
<tr>
<td>PR1-11</td>
<td>Hormones and chemoprevention</td>
</tr>
<tr>
<td>PR1-12</td>
<td>Modulators of arachidonic acid metabolism</td>
</tr>
<tr>
<td>PR1-13</td>
<td>Other</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>PR2</th>
<th>Clinical Prevention Studies</th>
</tr>
</thead>
<tbody>
<tr>
<td>PR2-01</td>
<td>Biomarkers and intervention studies</td>
</tr>
<tr>
<td>PR2-02</td>
<td>Chemoprevention trials</td>
</tr>
<tr>
<td>PR2-03</td>
<td>Studies at the interface of cancer prevention and chemotherapy</td>
</tr>
<tr>
<td>PR2-04</td>
<td>Physiological and lifestyle effects on chemoprevention</td>
</tr>
<tr>
<td>PR2-05</td>
<td>Prevention clinical trials</td>
</tr>
<tr>
<td>PR2-06</td>
<td>Prevention of second cancers</td>
</tr>
<tr>
<td>PR2-07</td>
<td>Prevention studies in high-risk populations</td>
</tr>
<tr>
<td>PR2-08</td>
<td>Other</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>CL</th>
<th>CLINICAL RESEARCH</th>
</tr>
</thead>
<tbody>
<tr>
<td>CL1</td>
<td>Phase I Clinical Trials</td>
</tr>
<tr>
<td>CL1-01</td>
<td>Phase I Clinical Trials</td>
</tr>
<tr>
<td>CL2</td>
<td>Phase II-III Clinical Trials</td>
</tr>
<tr>
<td>CL2-01</td>
<td>AIDS-related malignancies</td>
</tr>
<tr>
<td>CL2-02</td>
<td>Brain/central nervous system cancers</td>
</tr>
<tr>
<td>CL2-03</td>
<td>Breast cancer</td>
</tr>
<tr>
<td>CL2-04</td>
<td>Colon and other gastrointestinal cancers</td>
</tr>
<tr>
<td>CL2-05</td>
<td>Head and neck cancers</td>
</tr>
<tr>
<td>CL2-06</td>
<td>Leukemias and lymphomas</td>
</tr>
<tr>
<td>CL2-07</td>
<td>Lung cancer</td>
</tr>
<tr>
<td>CL2-08</td>
<td>Melanoma and skin cancer</td>
</tr>
<tr>
<td>CL2-09</td>
<td>Ovarian and other gynecological cancers</td>
</tr>
<tr>
<td>CL2-10</td>
<td>Pediatric malignancies</td>
</tr>
<tr>
<td>CL2-11</td>
<td>Prostate and other genitourinary tract cancers</td>
</tr>
<tr>
<td>CL2-12</td>
<td>Sarcomas</td>
</tr>
<tr>
<td>CL2-13</td>
<td>Other</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>CL3</th>
<th>Organ-Site Specific Studies: Preclinical Research (Tumor Biology/Translational Research/Experimental Therapeutics)</th>
</tr>
</thead>
<tbody>
<tr>
<td>CL3-01</td>
<td>AIDS-related malignancies</td>
</tr>
<tr>
<td>CL3-02</td>
<td>Brain/central nervous system cancers</td>
</tr>
<tr>
<td>CL3-03</td>
<td>Breast cancer</td>
</tr>
<tr>
<td>CL3-04</td>
<td>Colon and other gastrointestinal cancers</td>
</tr>
<tr>
<td>CL3-05</td>
<td>Head and neck cancers</td>
</tr>
<tr>
<td>CL3-06</td>
<td>Leukemias and lymphomas</td>
</tr>
<tr>
<td>CL3-07</td>
<td>Lung cancer</td>
</tr>
<tr>
<td>CL3-08</td>
<td>Melanoma and skin cancer</td>
</tr>
</tbody>
</table>

| CL3-09 | Ovarian and other gynecological cancers |
| CL3-10 | Pediatric malignancies |
| CL3-11 | Prostate and other genitourinary tract cancers |
| CL3-12 | Sarcomas |
| CL3-13 | Secondary cancers |
| CL3-14 | Animal/transgenic models of molecular progression |
| CL3-15 | Other |

<table>
<thead>
<tr>
<th>CL4</th>
<th>Clinical Pharmacology</th>
</tr>
</thead>
<tbody>
<tr>
<td>CL4-01</td>
<td>Clinical drug resistance</td>
</tr>
<tr>
<td>CL4-02</td>
<td>Clinical toxicology</td>
</tr>
<tr>
<td>CL4-03</td>
<td>Biodistribution/availability</td>
</tr>
<tr>
<td>CL4-04</td>
<td>Pharmaceutics and monitoring</td>
</tr>
<tr>
<td>CL4-05</td>
<td>Prodrugs and activation strategies</td>
</tr>
<tr>
<td>CL4-06</td>
<td>Other</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>CL5</th>
<th>Modality-Based Clinical Research</th>
</tr>
</thead>
<tbody>
<tr>
<td>CL5-01</td>
<td>Cell-based therapies</td>
</tr>
<tr>
<td>CL5-02</td>
<td>Differentiation therapy</td>
</tr>
<tr>
<td>CL5-03</td>
<td>Gene therapy clinical trials</td>
</tr>
<tr>
<td>CL5-04</td>
<td>Hematopoietic colony stimulating factors</td>
</tr>
<tr>
<td>CL5-05</td>
<td>Mechanism-based combination chemotherapy</td>
</tr>
<tr>
<td>CL5-06</td>
<td>Multimodality therapy</td>
</tr>
<tr>
<td>CL5-07</td>
<td>Adjuvant chemotherapy</td>
</tr>
<tr>
<td>CL5-08</td>
<td>Clinical reversal of multidrug resistance</td>
</tr>
<tr>
<td>CL5-09</td>
<td>Transplantation: bone marrow and other stem cell approaches</td>
</tr>
<tr>
<td>CL5-10</td>
<td>Alternative medicine research</td>
</tr>
<tr>
<td>CL5-11</td>
<td>Other</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>CL6</th>
<th>Molecular Biology/Oncology in the Clinic</th>
</tr>
</thead>
<tbody>
<tr>
<td>CL6-01</td>
<td>Advances in genome scanning relevant to the clinic</td>
</tr>
<tr>
<td>CL6-02</td>
<td>Comparative genomic hybridization from the bench to the clinic</td>
</tr>
<tr>
<td>CL6-03</td>
<td>Cytogenetics and clinical molecular genetics</td>
</tr>
<tr>
<td>CL6-04</td>
<td>Minimal residual disease</td>
</tr>
<tr>
<td>CL6-05</td>
<td>Molecular markers of metastasis and progression</td>
</tr>
<tr>
<td>CL6-06</td>
<td>Oncogene-based molecular diagnosis and prognosis</td>
</tr>
<tr>
<td>CL6-07</td>
<td>Tumor staging: correlation of clinical and molecular markers</td>
</tr>
<tr>
<td>CL6-08</td>
<td>Other</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>CL7</th>
<th>Supportive Care and Psychosocial Aspects of Cancer</th>
</tr>
</thead>
<tbody>
<tr>
<td>CL7-01</td>
<td>Cancer information access and dissemination</td>
</tr>
<tr>
<td>CL7-02</td>
<td>Pain research</td>
</tr>
<tr>
<td>CL7-03</td>
<td>Palliative care</td>
</tr>
<tr>
<td>CL7-04</td>
<td>Psychosocial aspects of cancer</td>
</tr>
<tr>
<td>CL7-05</td>
<td>Other</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>EN</th>
<th>ENDOCRINOLOGY/ PRECLINICAL AND CLINICAL</th>
</tr>
</thead>
<tbody>
<tr>
<td>EN1</td>
<td>Molecular and Preclinical Endocrinology: Receptors and Signal Transduction</td>
</tr>
<tr>
<td>EN1-01</td>
<td>Cytokines and receptors</td>
</tr>
<tr>
<td>EN1-02</td>
<td>Growth factors and cell surface receptors</td>
</tr>
<tr>
<td>EN1-03</td>
<td>Developmental control of hormone receptors</td>
</tr>
<tr>
<td>EN1-04</td>
<td>Hormonal control of cell growth and death</td>
</tr>
<tr>
<td>EN1-05</td>
<td>Hormone action and inhibitors</td>
</tr>
<tr>
<td>EN1-06</td>
<td>Hormones and differentiation</td>
</tr>
<tr>
<td>EN1-07</td>
<td>Hormone receptor networks: signal transduction</td>
</tr>
<tr>
<td>EN1-08</td>
<td>Nuclear receptors: structure and function</td>
</tr>
<tr>
<td>EN1-09</td>
<td>New ligands</td>
</tr>
<tr>
<td>EN1-10</td>
<td>Preclinical studies of endocrine-related cancers</td>
</tr>
<tr>
<td>--------</td>
<td>-----------------------------------------------</td>
</tr>
<tr>
<td>EN1-11</td>
<td>Protein-protein and co-factor interactions</td>
</tr>
<tr>
<td>EN1-12</td>
<td>Receptor crossstalk and signaling</td>
</tr>
<tr>
<td>EN1-13</td>
<td>Retinoid receptors</td>
</tr>
<tr>
<td>EN1-14</td>
<td>Steroid hormones and receptors</td>
</tr>
<tr>
<td>EN1-15</td>
<td>Thyroid hormones and receptors</td>
</tr>
<tr>
<td>EN1-16</td>
<td>Other</td>
</tr>
<tr>
<td>EN2</td>
<td>Clinical Endocrinology</td>
</tr>
<tr>
<td>EN2-01</td>
<td>Hormonal carcinogenesis</td>
</tr>
<tr>
<td>EN2-02</td>
<td>Retinoid-based cancer therapy</td>
</tr>
<tr>
<td>EN2-03</td>
<td>Hormone receptors and diagnosis/prognosis</td>
</tr>
<tr>
<td>EN2-04</td>
<td>Hormone synthesis, metabolism, and inhibitors</td>
</tr>
<tr>
<td>EN2-05</td>
<td>Neuroendocrine and other endocrine factors</td>
</tr>
<tr>
<td>EN2-06</td>
<td>Endocrine-related cancers: organ sites</td>
</tr>
<tr>
<td>EN2-07</td>
<td>Breast</td>
</tr>
<tr>
<td>EN2-08</td>
<td>Ectopic hormone production</td>
</tr>
<tr>
<td>EN2-09</td>
<td>Gynecological</td>
</tr>
<tr>
<td>EN2-10</td>
<td>Prostate/genitourinary</td>
</tr>
<tr>
<td>EN2-11</td>
<td>Other</td>
</tr>
<tr>
<td>IM</td>
<td>IMMUNOLOGY/PRECLINICAL AND CLINICAL</td>
</tr>
<tr>
<td>IM1</td>
<td>Tumor Immunobiology: Experimental and Preclinical</td>
</tr>
<tr>
<td>IM1-01</td>
<td>Animal/transgenic models for tumor immunology</td>
</tr>
<tr>
<td>IM1-02</td>
<td>Antigenic modulation</td>
</tr>
<tr>
<td>IM1-03</td>
<td>DNA-based vaccines</td>
</tr>
<tr>
<td>IM1-04</td>
<td>Oncogene-directed immunotherapy/vaccines</td>
</tr>
<tr>
<td>IM1-05</td>
<td>Tumor suppressor-directed immunotherapy/vaccines</td>
</tr>
<tr>
<td>IM1-06</td>
<td>Viral immunology and vaccines</td>
</tr>
<tr>
<td>IM1-07</td>
<td>Immunodeficiency/immunosuppression (including AIDS and AIDS-related malignancies)</td>
</tr>
<tr>
<td>IM1-08</td>
<td>Immunomodulation</td>
</tr>
<tr>
<td>IM1-09</td>
<td>Integins and cell adhesion molecules</td>
</tr>
<tr>
<td>IM1-10</td>
<td>Lymphokines, cytokines, and growth factors</td>
</tr>
<tr>
<td>IM1-11</td>
<td>Non-specific effector mechanisms</td>
</tr>
<tr>
<td>IM1-12</td>
<td>Specific immunomechanisms</td>
</tr>
<tr>
<td>IM1-13</td>
<td>Tumor antigens</td>
</tr>
<tr>
<td>IM1-14</td>
<td>Other</td>
</tr>
<tr>
<td>IM2</td>
<td>Clinical Immunology: Biological Therapy</td>
</tr>
<tr>
<td>IM2-01</td>
<td>Antibodies/immunocongjugates</td>
</tr>
<tr>
<td>IM2-02</td>
<td>Cancer vaccines</td>
</tr>
<tr>
<td>IM2-03</td>
<td>Cellular immunotherapy</td>
</tr>
<tr>
<td>IM2-04</td>
<td>Lymphokines and growth factors</td>
</tr>
<tr>
<td>IM2-05</td>
<td>Immunodiagnosis</td>
</tr>
<tr>
<td>IM2-06</td>
<td>Immunotherapy of human cancer</td>
</tr>
<tr>
<td>IM2-07</td>
<td>Transplantation: control of rejection</td>
</tr>
<tr>
<td>IM2-08</td>
<td>Other</td>
</tr>
<tr>
<td>PT</td>
<td>PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS</td>
</tr>
<tr>
<td>PT1</td>
<td>Drug Discovery: Design, Screening, and Delivery</td>
</tr>
<tr>
<td>PT1-01</td>
<td>Human xenograft models for drug discovery</td>
</tr>
<tr>
<td>PT1-02</td>
<td>Biochemical modulators of the therapeutic index</td>
</tr>
<tr>
<td>PT1-03</td>
<td>Combination chemotherapy</td>
</tr>
<tr>
<td>PT1-04</td>
<td>Differentiation therapy</td>
</tr>
<tr>
<td>PT1-05</td>
<td>Drug design: rational/empirical</td>
</tr>
<tr>
<td>PT1-06</td>
<td>Combinatorial chemistry-based drug design</td>
</tr>
<tr>
<td>PT1-07</td>
<td>Drug screening</td>
</tr>
<tr>
<td>PT1-08</td>
<td>New targets</td>
</tr>
<tr>
<td>PT1-09</td>
<td>Novel drug delivery systems</td>
</tr>
<tr>
<td>PT1-10</td>
<td>Other</td>
</tr>
<tr>
<td>PT2</td>
<td>Mechanisms of Drug Action</td>
</tr>
<tr>
<td>PT2-01</td>
<td>Cell cycle mechanisms for anticancer drug action</td>
</tr>
<tr>
<td>PT2-02</td>
<td>Cellular responses to anticancer drugs</td>
</tr>
<tr>
<td>PT2-03</td>
<td>Drug-mediated stimulation of cell death pathways</td>
</tr>
<tr>
<td>PT2-04</td>
<td>Intracellular targets</td>
</tr>
<tr>
<td>PT2-05</td>
<td>Modulation of DNA repair</td>
</tr>
<tr>
<td>PT2-06</td>
<td>Oncogenic transcription factors as targets</td>
</tr>
<tr>
<td>PT2-07</td>
<td>Secondary targets</td>
</tr>
<tr>
<td>PT2-08</td>
<td>Other</td>
</tr>
<tr>
<td>PT3</td>
<td>Drug Resistance I - Multidrug Resistance</td>
</tr>
<tr>
<td>PT3-01</td>
<td>Biochemistry of membrane metabolism and transport</td>
</tr>
<tr>
<td>PT3-02</td>
<td>Drug transport and metabolism</td>
</tr>
<tr>
<td>PT3-03</td>
<td>Non-p-glycoprotein multidrug resistance</td>
</tr>
<tr>
<td>PT3-04</td>
<td>P-glycoprotein structure and function</td>
</tr>
<tr>
<td>PT3-05</td>
<td>Reversal of multidrug resistance (preclinical)</td>
</tr>
<tr>
<td>PT3-06</td>
<td>Other</td>
</tr>
<tr>
<td>PT4</td>
<td>Drug Resistance II</td>
</tr>
<tr>
<td>PT4-01</td>
<td>Drug transport and metabolism</td>
</tr>
<tr>
<td>PT4-02</td>
<td>Glutathione metabolism</td>
</tr>
<tr>
<td>PT4-03</td>
<td>Natural products, synthetic drugs, and nucleotide analogs</td>
</tr>
<tr>
<td>PT4-04</td>
<td>Novel mechanisms</td>
</tr>
<tr>
<td>PT4-05</td>
<td>Regulation of gene expression in drug resistance</td>
</tr>
<tr>
<td>PT4-06</td>
<td>Reversal of drug resistance</td>
</tr>
<tr>
<td>PT4-07</td>
<td>Other</td>
</tr>
<tr>
<td>PT5</td>
<td>Pharmacology and Preclinical Toxicology</td>
</tr>
<tr>
<td>PT5-01</td>
<td>Cellular pharmacology</td>
</tr>
<tr>
<td>PT5-02</td>
<td>Pharmacogenetics</td>
</tr>
<tr>
<td>PT5-03</td>
<td>Pharmacokinetics and pharmacodynamics</td>
</tr>
<tr>
<td>PT5-04</td>
<td>Preclinical toxicology</td>
</tr>
<tr>
<td>PT5-05</td>
<td>Other</td>
</tr>
<tr>
<td>PT6</td>
<td>Therapeutic Agents I (Small Molecule Approaches)</td>
</tr>
<tr>
<td>PT6-01</td>
<td>Alkylyating agents</td>
</tr>
<tr>
<td>PT6-02</td>
<td>Antifolates</td>
</tr>
<tr>
<td>PT6-03</td>
<td>Chemopreventive therapeutic agents</td>
</tr>
<tr>
<td>PT6-04</td>
<td>Ether lipids</td>
</tr>
<tr>
<td>PT6-05</td>
<td>FarnesyI transferase inhibitors</td>
</tr>
<tr>
<td>PT6-06</td>
<td>Novel antimumor agents</td>
</tr>
<tr>
<td>PT6-07</td>
<td>Oncogene-based therapeutic small molecules and Platinum complexes</td>
</tr>
<tr>
<td>PT6-08</td>
<td>Tyrosine kinase and phosphatase inhibitors</td>
</tr>
<tr>
<td>PT6-09</td>
<td>Other</td>
</tr>
<tr>
<td>PT7</td>
<td>Therapeutic Agents II (Biological Approaches)</td>
</tr>
<tr>
<td>PT7-01</td>
<td>Antireceptors</td>
</tr>
<tr>
<td>PT7-02</td>
<td>Antisense oligonucleotides</td>
</tr>
<tr>
<td>PT7-03</td>
<td>Antiviral therapy</td>
</tr>
<tr>
<td>PT7-04</td>
<td>Apoptosis: therapeutic manipulation</td>
</tr>
<tr>
<td>PT7-05</td>
<td>Growth factor receptors and other surface antigens as targets for therapy</td>
</tr>
<tr>
<td>PT7-06</td>
<td>Oncogenes, tumor suppressor genes, and gene products as targets for therapy</td>
</tr>
<tr>
<td>PT7-07</td>
<td>Protein kinases and phosphatases as targets for therapy</td>
</tr>
<tr>
<td>PT7-08</td>
<td>Other</td>
</tr>
<tr>
<td>PT8</td>
<td>Experimental Gene Therapy</td>
</tr>
<tr>
<td>PT8-01</td>
<td>Vector systems and targeting strategies</td>
</tr>
<tr>
<td>PT8-02</td>
<td>Cell-type targeted vectors</td>
</tr>
<tr>
<td>PT8-03</td>
<td>TK-based suicide gene therapy</td>
</tr>
<tr>
<td>PT8-04</td>
<td>Cell-type specific expression regulation of suicide genes</td>
</tr>
<tr>
<td>PT8-05</td>
<td>Antisense/ribosome decay</td>
</tr>
<tr>
<td>PT8-06</td>
<td>Delivery systems: nonbiological, e.g. liposomes</td>
</tr>
<tr>
<td>PT8-07</td>
<td>Hematopoietic progenitor cell targeting</td>
</tr>
<tr>
<td>PT8-08</td>
<td>Other</td>
</tr>
<tr>
<td>PT9</td>
<td>Topoisomerases, Other DNA-reactive Agents, Tubulin Agents</td>
</tr>
<tr>
<td>PT9-01</td>
<td>DNA-reactive agents</td>
</tr>
<tr>
<td>PT9-02</td>
<td>Topoisomerases</td>
</tr>
<tr>
<td>PT9-03</td>
<td>Tubulin agents</td>
</tr>
<tr>
<td>PT9-04</td>
<td>Other</td>
</tr>
<tr>
<td>RR</td>
<td>RADIOTHERAPY/RADIATION ONCOLOGY</td>
</tr>
<tr>
<td>RR1</td>
<td>Experimental Radiotherapy</td>
</tr>
<tr>
<td>RR1-01</td>
<td>ATM: structure-function</td>
</tr>
<tr>
<td>RR1-02</td>
<td>ATM: genomic aspects and mutations</td>
</tr>
<tr>
<td>RR1-03</td>
<td>Cell cycle, differentiation, and apoptosis in radiation responses</td>
</tr>
<tr>
<td>RR1-04</td>
<td>Cytogenetic responses to radiation</td>
</tr>
<tr>
<td>RR1-05</td>
<td>DNA damage, mutagenesis, and repair</td>
</tr>
<tr>
<td>RR1-06</td>
<td>Experimental radiotherapeutics</td>
</tr>
<tr>
<td>RR1-07</td>
<td>Genetic and epigenetic control of radiosensitivity</td>
</tr>
<tr>
<td>RR1-08</td>
<td>Hyperthermia</td>
</tr>
<tr>
<td>RR1-09</td>
<td>Membrane targets for radiation</td>
</tr>
<tr>
<td>RR1-10</td>
<td>Molecular mechanisms/radiation-induced gene expression</td>
</tr>
<tr>
<td>RR1-11</td>
<td>Photobiology</td>
</tr>
<tr>
<td>RR1-12</td>
<td>Photodynamic therapy</td>
</tr>
<tr>
<td>RR1-13</td>
<td>Predictive assays for radiation sensitivity</td>
</tr>
<tr>
<td>RR1-14</td>
<td>Oncogenes and tumor suppressor genes in radiation responses</td>
</tr>
<tr>
<td>RR1-15</td>
<td>Radiation-induced biochemical alterations: conformation and function</td>
</tr>
<tr>
<td>RR1-16</td>
<td>Radiation-induced transformation and carcinogenesis</td>
</tr>
<tr>
<td>RR1-17</td>
<td>Radiation resistance</td>
</tr>
<tr>
<td>RR1-18</td>
<td>Radiolabeled antibodies in diagnosis and localization</td>
</tr>
<tr>
<td>RR1-19</td>
<td>Radiobiology and radiosensitizers</td>
</tr>
<tr>
<td>RR1-20</td>
<td>Tumor oxygenation and modification</td>
</tr>
<tr>
<td>RR1-21</td>
<td>Other</td>
</tr>
<tr>
<td>RR2</td>
<td>Radiation Oncology, Preclinical and Clinical</td>
</tr>
<tr>
<td>RR2-01</td>
<td>Clinical radiotherapeutic studies</td>
</tr>
<tr>
<td>RR2-02</td>
<td>Combination therapies</td>
</tr>
<tr>
<td>RR2-03</td>
<td>Drug-radiation interactions</td>
</tr>
<tr>
<td>RR2-04</td>
<td>Modification of radiation sensitivity and injury</td>
</tr>
<tr>
<td>RR2-05</td>
<td>Radiation-induced late effects - second cancers</td>
</tr>
<tr>
<td>RR2-06</td>
<td>Radiation resistance</td>
</tr>
<tr>
<td>RR2-07</td>
<td>Radiolabeled antibodies in diagnosis and localization</td>
</tr>
<tr>
<td>RR2-08</td>
<td>Radioprotectors and radiosensitizers</td>
</tr>
<tr>
<td>RR2-09</td>
<td>Other</td>
</tr>
</tbody>
</table>
COPYRIGHT TRANSFER/CONFLICT OF INTEREST DISCLOSURE FORM

Your abstract will not be considered unless this form is completed, signed, and enclosed with your submission.

NAME OF PRESENTER: ____________________________

TITLE OF ABSTRACT: ____________________________

COPYRIGHT TRANSFER

As the PRESENTER and as an author of this abstract, on behalf of all the authors (check appropriate box and affix signature):

☐ I hereby transfer copyright of this abstract to the American Association for Cancer Research (AACR), Inc., in the event that this abstract is published in the Proceedings of the American Association for Cancer Research. I understand by this transfer that the authors relinquish all exclusive rights of copyright ownership to the abstract, including without limitation all rights of reproduction, derivation, distribution, sale, and display of the work, in whole or in part, in any and all forms of media now or hereafter known. I understand the AACR, Inc., as copyright owner, has sole authority to grant permission to reproduce the abstract.

☐ This abstract was prepared by an employee or employees of the United States Federal Government. Therefore, I am unable to transfer rights to AACR, Inc.

Signature of Presenter ____________________________ Date ______________

CONFLICT OF INTEREST DISCLOSURE

The American Association for Cancer Research (AACR) is committed to ensuring the integrity of its scientific, educational, and research programs and therefore requires disclosure of any financial or other interests which might be construed as resulting in an actual, potential, or apparent conflict. The existence of financial interests or other relationships of a commercial nature is not regarded by the AACR as creating a presumption of impropriety. Rather, AACR's policy represents a recognition of the many factors which can influence judgments about research data and a desire to make as much information as possible available to those reviewing the data.

The PRESENTER is required to disclose any financial or other relationships with an entity having a commercial interest in the particular subject matter of his or her abstract. A commercial interest exists not only where the entity's products or services are the subject of the abstract, but also where the entity's products or services are in competition with those under consideration. This form must be submitted by all PRESENTERS of abstracts whether or not there is such a relationship. Please indicate if you or any individual with whom you directly share income has a relationship requiring disclosure, including:

<table>
<thead>
<tr>
<th>NO</th>
<th>YES</th>
</tr>
</thead>
<tbody>
<tr>
<td>☐</td>
<td>☐</td>
</tr>
<tr>
<td>☐</td>
<td>☐</td>
</tr>
<tr>
<td>☐</td>
<td>☐</td>
</tr>
<tr>
<td>☐</td>
<td>☐</td>
</tr>
<tr>
<td>☐</td>
<td>☐</td>
</tr>
<tr>
<td>☐</td>
<td>☐</td>
</tr>
<tr>
<td>☐</td>
<td>☐</td>
</tr>
<tr>
<td>☐</td>
<td>☐</td>
</tr>
</tbody>
</table>

IF YOU ANSWERED YES TO ANY OF THESE QUESTIONS, PLEASE DESCRIBE THE NATURE OF THE INTEREST AND/OR RELATIONSHIP, IDENTIFYING THE RELEVANT COMMERCIAL ENTITY (attach additional sheets as required).

__________________________________________________________________________

__________________________________________________________________________

__________________________________________________________________________

I represent that the information reported above is accurate. I understand that, where appropriate, this information may be disclosed publicly. I further understand that the AACR reserves the right to replace me in a scientific or educational program, decline to publish my work, or otherwise limit my participation in the annual meeting if it believes that a significant conflict of interest exists. Finally, I understand that failure to complete this Disclosure Form will disqualify me from making a presentation at the annual meeting.

Submitted by: ____________________________ Date: ____________________________

Signature of Presenter
ABSTRACT FORM
AACR Annual Meeting
March 28-April 1, 1998
New Orleans, LA

Analysis of nucleotide-binding site mutants indicates a non-efflux component in P-glycoprotein-mediated drug resistance. Schott, B., Morse, B.S., Polonskaia, M., Stein, W., Mechetner, E.B., Chen, T.L., Chisholm, R.L., and Roninson, I.B. University of Illinois at Chicago, Chicago, IL 60607, Hebrew University, Jerusalem, Israel 91904, Oncotech, Inc., Irvine, CA 92714, Northwestern University, Chicago, IL 60611.

P-glycoprotein (Pgp), a multidrug resistance efflux pump, contains two nucleotide-binding sites (NBS) responsible for its ATPase activity. We have introduced K→M substitutions at positions 433 and/or 1076 of the two NBS of the human MDR1 Pgp. Analysis of LMTk- transfectants expressing different Pgp mutants showed that simultaneous mutation of both NBS results in complete loss of the ability to confer drug resistance. Pgp's carrying mutations in either one of the two ABC retained about 15% of the ability to confer resistance to vinblastine and vincristine, but not to other Pgp-transported drugs. Single-mutant Pgps showed decreased binding of a photoactive ATP analog and complete or nearly complete loss of ATPase activity. Wild-type and single-mutant transfectants that were equally resistant to vinblastine drastically differed in their vinblastine transport. Vinblastine accumulation and efflux in single-mutant transfectants was similar to control cells rather than to wild-type Pgp transfectants. Confocal microscopy analysis of intracellular distribution of a fluorescent vinblastine derivative revealed plasma membrane staining which was specific to single-mutant transfectants. Vinblastine resistance and membrane staining in the transfectants were similarly affected by anti-Pgp monoclonal antibody UIC2. These results suggest that plasma membrane sequestration is a component of Pgp-mediated drug resistance.

Deadline: October 28, 1997
Enclose: Original abstract form plus 3 photocopies. (This form must be filled out completely. Requested signatures must appear on all copies.)
Your floppy disk, if you are submitting a copy of your abstract on disk
Check for US$40 payable to AACR, Inc. OR authorization to charge
US$40 to credit card (see Item 8, below).
A completed and signed original plus 1 copy of the Copyright Transfer/Conflict of Interest Disclosure Form
Acknowledgment Card (completed and stamped).
A self-addressed, stamped envelope.

1. Category and Subclassification (see Pages 8-10): Type the five-character code in the blocks provided, for example, B.L.T. 0 4

2. Abstract is SPONSORED by: 2309
   Member No.
   (See Directory of Members for Member No.)
Igor Boris Roninson
   Name
   (Please Print)
University of Illinois at Chicago
   Address
900 South Ashland
   City, State
Chicago, Illinois
   Zip/Postal Code
60607
   USA/Country
   Telephone No. 312-996-3486 FAX No. roninson@uic.edu

3. As the SPONSOR of this abstract and on behalf of all the authors, I hereby indicate my support for the data contained herein.
   Igor Boris Roninson
   Signature of SPONSOR

4. (Complete only if SPONSOR is an Associate Member) I, the undersigned Active or Corresponding Member in good standing, Emeritus, or Honorary Member, endorse the content of this abstract, for which the above-named Associate Member is sponsor and presenter. (See regulations applying to Associate Members on Page 3.)
   Name
   (Please Print)
   Signature
   Member No.

5. Eligibility for Young Investigator Awards (American and International)

☐ A. The PRESENTER of this abstract is a medical or graduate student, physician in training, or postdoctoral fellow.
☐ B. The PRESENTER meets the criteria in Box A above and is also a minority scientist as defined by the National Cancer Institute (see Page 5).

Please check all the information you have entered for correctness and adherence to AACR submission rules. Infractions of sponsorship regulations will result in the rejection and return of the abstract to the SPONSOR without consideration by the Program Committee. Infractions of format, including forms submitted without the required signatures, will result in a fee of US$40 which will be billed to the SPONSOR.

6. Abstract is to be PRESENTED by: 
   Member No.
   (If an AACR Member.)
   Name
   (Please Print)
   University of Illinois at Chicago
   Address
900 South Ashland
   City, State
Chicago, Illinois
   Zip/Postal Code
60607
   USA/Country
   Telephone No. 312-413-3128 FAX No. bschott@uic.edu

7. As the PRESENTER and as an author of this abstract and on behalf of all the authors, I hereby give exclusive permission to the American Association for Cancer Research, Inc. to record my presentation at the 1998 Annual Meeting and to collect all revenue from subsequent audiotape sales. I also acknowledge that I am enclosing a completed, signed original and 1 copy of the Copyright Transfer/Conflict of Interest Disclosure Form.
   Brigitte Schott
   Signature of PRESENTER

   Check is enclosed. Please list name of PRESENTER on the check.
   I authorize you to charge my credit card for the abstract submission fee.
   ☐ VISA       ☐ MasterCard       ☐ American Express
   Card No.       Expiration Date
   Cardholder Name (PRINT)     Signature

9. Please check the signature block on the right-hand page of this form for accuracy.
Deadline: October 28, 1997
Enclose:
- Original abstract form plus 3 photocopies. (This form must be filled out completely. Requested signatures must appear on all copies.)
- Your floppy disk, if you are submitting a copy of your abstract on disk.
- Check for US$40 payable to AACR, Inc., OR authorization to charge US$40 to credit card (see Item 8, below).
- A completed and signed original plus 1 copy of the Copyright Transfer/Conflict of Interest Disclosure Form
- Acknowledgment Type
- A self-addressed, stamped envelope.

1. Category and Subclassification (see Pages 8-10): Type the five-character code in the blocks provided, for example,

| B | L | I | 0 | 1 |

Type abstract within black lines. See sample abstract.

2. Abstract is SPONSORED by: ________________Member No.
(See Directory of Members for Member No.)
________________________Name
(Please Print)
________________________Address
________________________City, State
________________________Zip/Postal Code ________Country
________________________Telephone No. ___________FAX No.
________________________E-Mail Address

3. As the SPONSOR of this abstract and on behalf of all the authors, I hereby indicate my support for the data contained herein.

________________________Signature of SPONSOR

4. (Complete only if SPONSOR is an Associate Member) I, the undersigned Active or Corresponding Member in good standing, Emeritus, or Honorary Member, endorse the content of this abstract, for which the above-named Associate Member is sponsor and presenter. (See regulations applying to Associate Members on Page 3.)

________________________Name
(Please Print)
________________________Signature ________________Member No.

5. Eligibility for Young Investigator Awards (American and International)

□ A. The PRESENTER of this abstract is a medical or graduate student, physician in training, or postdoctoral fellow.

□ B. The PRESENTER meets the criteria in Box A above and is also a minority scientist as defined by the National Cancer Institute (see Page 5).

6. Abstract is to be PRESENTED by: ________________Member No.
(If an AACR Member.)
________________________Name
(Please Print)
________________________Address
________________________City, State
________________________Zip/Postal Code ________Country
________________________Telephone No. ___________FAX No.
________________________E-Mail Address

7. As the PRESENTER and as an author of this abstract and on behalf of all the authors, I hereby give exclusive permission to the American Association for Cancer Research, Inc. to record my presentation at the 1998 Annual Meeting and to collect all revenue from subsequent audiocassette sales. I also acknowledge that I am enclosing a completed, signed original and 1 copy of the Copyright Transfer/Conflict of Interest Disclosure Form.

________________________Signature of PRESENTER


☐ Check is enclosed. Please list name of PRESENTER on the check.
☐ I authorize you to charge my credit card for the abstract submission fee.

☐ VISA ☐ MasterCard ☐ American Express

________________________Card holder Name (PRINT)
________________________Expiry Date
________________________Signature

Please check all the information you have entered for correctness and adherence to AACR submission rules. Infractions of sponsor-sponsored regulations will result in the rejection and return of the abstract to the SPONSOR without consideration by the Program Committee. Infractions of format, including forms submitted without the required signatures, will result in a fee of US$40 which will be billed to the SPONSOR.
ABSTRACT FORM
AACR Annual Meeting
March 28-April 1, 1998
New Orleans, LA

Deadline: October 28, 1997
Enclose:

Original abstract form plus
3 photocopies. (This form
must be filled out
completely. Requested
signatures must appear on
all copies.)

Your floppy disk, if you are
submitting a copy of your
abstract on disk

Check for US$40 payable to
AACR, Inc., OR
authorization to charge
US$40 to credit card
(see Item 8, below).

A completed and signed
original plus 1 copy of the
Copyright Transfer/Conflict
of Interest Disclosure Form

Acknowledgment Card
(completed and stamped).

A self-addressed, stamped
envelope.

1. Category and Subclassification
(see Pages 8-10): Type the five-character
code in the blocks provided. for example,

B E T 1 - 0 1

2. Abstract is SPONSORED by: ________Member No.
(See Directory of Members for Member No.)

________________________Member Name
(Please Print)
________________________Address
________________________City, State
________________________City, State
________________________Phone No. __________________Fax No.
________________________E-Mail Address

3. As the SPONSOR of this abstract and on behalf of all the authors, I hereby
indicate my support for the data contained herein.

________________________Signature of SPONSOR

4. (Complete only if SPONSOR is an Associate Member) I, the undersigned
Active or Corresponding Member in good standing, Emeritus, or Honorary
Member, endorse the content of this abstract, for which the above-named
Associate Member is sponsor and presenter. (See regulations applying to
Associate Members on Page 3.)

________________________Name
(Please Print)

________________________Signature ________Member No.

5. Eligibility for Young Investigator Awards (American and International)
☐ A. The PRESENTER of this abstract is a medical or graduate student,
physician in training, or postdoctoral fellow.
☐ B. The PRESENTER meets the criteria in Box A above and is also a
minority scientist as defined by the National Cancer Institute (see Page 5).

Please check all the information you have entered for correctness and adherence to AACR submission rules. Infractions of sponsorship regulations will result in
the rejection and return of the abstract to the SPONSOR without consideration by the Program Committee. Infractions of format, including forms submitted without
the required signatures, will result in a fee of US$40 which will be billed to the SPONSOR.

6. Abstract is to be PRESENTED by: ________Member No.
(If an AACR Member.)

________________________Name
(Please Print)
________________________Address
________________________City, State
________________________City, State
________________________Phone No. __________________Fax No.
________________________E-Mail Address

7. As the PRESENTER and as an author of this abstract and on behalf of all the
authors, I hereby give exclusive permission to the American Association
for Cancer Research, Inc. to record my presentation at the 1998 Annual
Meeting and to collect all revenue from subsequent audiocassette sales. I also
acknowledge that I am enclosing a completed, signed original and 1 copy of
the Copyright Transfer/Conflict of Interest Disclosure Form.

________________________Signature of PRESENTER


☐Check is enclosed. Please list name of PRESENTER on the check.

☐I authorize you to charge my credit card for the abstract submission fee.
☐VISA ☐MasterCard ☐American Express

________________________Card No.
________________________Expiration Date

________________________Cardholder Name (PRINT) ________Signature

15
AMERICAN ASSOCIATION FOR CANCER RESEARCH

Guidelines for Application for Active and Corresponding Membership

BENEFITS OF MEMBERSHIP

The American Association for Cancer Research (AACR), a scientific society of over 13,000 laboratory and clinical cancer researchers, was founded in 1907 to facilitate communication and dissemination of knowledge among scientists and others dedicated to the cancer problem; to foster research in cancer and related biomedical sciences; to encourage the presentation and discussion of new and important observations in the field; to foster public education, science education, and training; and to advance the understanding of cancer etiology, prevention, diagnosis, and treatment throughout the world.

Members of the AACR enjoy the following benefits:
1. the privilege of sponsoring a proffered paper (abstract) for consideration for presentation at the AACR annual meeting;
2. subscriptions to the Association's high-quality journals Cancer Research, Clinical Cancer Research, Cell Growth & Differentiation, and Cancer Epidemiology, Biomarkers & Prevention at reduced member rates;
3. an advance copy of the Program and Proceedings of the American Association for Cancer Research that contains over 4,000 abstracts of proffered papers presented at the annual meeting;
4. reduced registration rates at annual meetings;
5. priority notice of small, focused meetings in the AACR's exciting series of Special Conferences in Cancer Research;
6. substantially reduced registration rates for Special Conferences;
7. opportunities for participation in AACR meetings in North America and abroad with other scientific societies around the world;
8. receipt of AACR Newsletters and other important announcements;
9. early notification of and reduced rates for participation in the AACR Employment Register;
10. an up-to-date Membership Directory of over 13,000 member researchers in the cancer field;
11. the professional benefits of AACR's public education activities concerning funding for cancer research and press coverage of the latest research findings;
12. the opportunity to participate in three Summer Workshops that foster knowledge in the cancer field for young investigators;
13. the facilitation of informal scientific exchange with leading researchers in the cancer field; and
14. many more ongoing benefits.

QUALIFICATIONS FOR MEMBERSHIP

Active membership in the AACR is open to investigators who live in the Americas. Individuals who have conducted two years of research resulting in peer-reviewed publications relevant to cancer, or who have made substantial contributions to cancer research in an administrative or educational capacity, are eligible. If a candidate has conducted research in an area of biomedical science related to cancer, he or she will qualify for membership. Evidence of patents relevant to cancer research may be submitted as qualifications for membership in lieu of peer-reviewed publications.

Corresponding membership is open to persons who are not residents of the Americas. The qualifications for corresponding membership are the same as those indicated above for active membership. Visiting scientists from outside the Americas who intend to return to their countries of origin by the anticipated time of election should apply for corresponding membership. All other visiting scientists should apply for active membership and transfer to corresponding status upon leaving the Americas.

Graduate and medical students, postdoctoral fellows, and physicians in training who do not yet meet the above qualifications for active or corresponding membership should apply for associate membership. Forms for associate membership are available from the AACR Office.

PROCEDURES FOR APPLICATION

There are three deadlines for the receipt of a membership application: January 1, May 1, and September 1 of each year. The Membership Committee will review all complete applications for active membership that have been received by these deadlines and will submit recommendations on each candidate to the Board of Directors which formally elects all members. The same procedure is followed by the Special Memberships Committee which receives applications for corresponding membership. Candidates will be notified according to the following schedule:

<table>
<thead>
<tr>
<th>Receipt of Application</th>
<th>Notification of Candidate</th>
</tr>
</thead>
<tbody>
<tr>
<td>in AACR Office</td>
<td>March</td>
</tr>
<tr>
<td>January 1</td>
<td></td>
</tr>
<tr>
<td>May 1</td>
<td>July</td>
</tr>
<tr>
<td>September 1</td>
<td>November</td>
</tr>
</tbody>
</table>

A complete application consists of the following material:

1. 6 copies of the form on the opposite side of this page, with all requested information provided.
2. 5 copies of the candidate's most current curriculum vitae and bibliography.
3. 5 copies of a letter of recommendation from a nominator who is an active, corresponding, emeritus, or honorary member of the AACR (at least one copy must be a signed, original letter). This letter should describe the candidate's achievements in laboratory research, clinical investigations, or epidemiological research, and it should affirm that this research adheres to accepted ethical scientific standards. --OR-- The nominator may sign the application form where indicated under the heading, "STATEMENT OF SUPPORT" (at least one copy of the form must be the signed original).
4. 5 copies of a letter of recommendation as described in Item 3 above from a secondor who is an active, corresponding, emeritus, or honorary member of the AACR (at least one copy must be a signed, original letter). --OR-- The secondor may sign the application form where indicated under the heading, "STATEMENT OF SUPPORT" (at least one copy of the form must be the signed original).
5. 5 reprints of each of two publications on which the candidate appears as author. As noted above, evidence of patents developed by the candidate may be submitted in lieu of one or both of the publications. If submitting patents, supply patent number and year awarded.

All material should be collated into five complete sets with the original application form as a covering document and sent to the address given below. Questions regarding procedures for membership application may also be directed to the following address:

Membership Services Department
American Association for Cancer Research
Public Ledger Building, Suite 826
150 S. Independence Mall West
Philadelphia, PA 19106-3483
Phone: 215/440-9300
FAX: 215/440-9412
E-mail: aacr@aacr.org

RESPONSIBILITIES OF MEMBERSHIP

Candidates should be aware of the following responsibilities of membership in the AACR. Active members must pay annual dues. In 1998 annual dues for active members are $175, $100 of which is designated for AACR journal subscriptions. Newly elected members of the AACR who have already purchased subscriptions to Cancer Research, Clinical Cancer Research, Cell Growth & Differentiation, or Cancer Epidemiology, Biomarkers & Prevention at the higher, nonmember rate will receive reimbursement of the unused portion of those subscriptions once their first year's membership dues are paid in full.

Corresponding members are required to pay dues ($90 in 1998) and may, if they wish, subscribe to Cancer Research, Clinical Cancer Research, Cell Growth & Differentiation, or Cancer Epidemiology, Biomarkers & Prevention at reduced member rates.

Applicants elected in March will be responsible for payment of that year's dues; applicants elected in July and November will pay dues for the following year. Applicants elected in March and July will be eligible to sponsor an abstract for the next annual meeting. Every effort will be made to afford the same opportunity to applicants elected in November.

Margaret Fori, Ph.D.
Executive Director
Application for Active or Corresponding Membership

NAME OF CANDIDATE: ____________________________________________

DATE OF BIRTH: ________________________________________________

PRESENT POSITION/TITLE: ________________________________________

INSTITUTIONAL AFFILIATION: _____________________________________

INSTITUTIONAL ADDRESS: ____________________________

(City) (State/Province) (Country) (Postal Code)

TELEPHONE NUMBER: ___________________________________________

(Fax number outside the United States list country and city codes.)

FAX NUMBER: _________________________________________________

E-MAIL ADDRESS: ______________________________________________

PRIMARY FIELD OF RESEARCH (Please check only one):

- Biochemistry and Biophysics
- Biostatistics
- Cellular Biology and Genetics
- Clinical Investigations
- Epidemiology
- Immunology
- Preclinical Pharmacology and Experimental Therapeutics
- Virology
- Carcinogenesis
- Endocrinology
- Molecular Biology and Genetics
- Other: ________________________________________________ (Please specify)

ACADEMIC DEGREES (Including where and when granted)

______________________________________________________________

______________________________________________________________

______________________________________________________________

EXPERIENCE SINCE HIGHEST DEGREE WAS GRANTED (Please list most recent first)

______________________________________________________________

______________________________________________________________

______________________________________________________________

PUBLICATIONS (Reprints of two peer-reviewed articles on which the candidate appears as an author must accompany this application. For these two articles list the authors, title, journal, volume, inclusive pages, and year. Do not submit abstracts. If submitting patents, supply patent number and year awarded.)

______________________________________________________________

______________________________________________________________

______________________________________________________________

CANDIDATE IS APPLYING FOR (Check one):  □ Active Membership  □ Corresponding Membership

CANDIDATE NOMINATED BY*: ____________________________ (Please print)

CANDIDATE SECONDED BY*: ________________________________ (Please print)

STATEMENT OF SUPPORT

Instead of submitting letters of recommendation, either the nominator or the seconder or both may complete the following section:

I acknowledge by signing this statement of support, that this candidate adheres to accepted ethical scientific standards and has or will make a long-term contribution to cancer research.

Signature of Nominator: __________________________________________ Date: ___________________

Signature of Seconder: ___________________________________________ Date: __________________
QUALIFICATIONS FOR MEMBERSHIP

Associate membership is open to graduate students, medical students, postdoctoral fellows, and physicians in training who are following a course of study or who are working in a research program relevant to cancer. Scientists in training who already have a substantial record of publications may wish to apply for active or corresponding membership which confer full benefits of membership.

BENEFITS OF MEMBERSHIP

The American Association for Cancer Research (AACR), a scientific society consisting of laboratory and clinical cancer researchers, was founded in 1907 to facilitate communication and dissemination of knowledge among scientists and others dedicated to the cancer problem; to foster research in cancer and related biomedical sciences; to encourage presentation and discussion of new and important observations in the field; to foster public education, science education, and training; and to advance the understanding of cancer etiology, prevention, diagnosis, and treatment throughout the world. Associate members of the AACR enjoy the following benefits:

1. the privilege of sponsoring a proffered paper (abstract) for consideration for presentation at the AACR annual meeting provided that (a) the associate member is the presenter of the paper and (b) an active, corresponding, emeritus, or honorary member in good standing of the AACR also signs the abstract of the paper in support of the work. (In this instance, the member who cosigns the abstract does not lose his or her own sponsorship privilege.);

2. optional subscriptions to the Association's high-quality journals: Cancer Research, Clinical Cancer Research, Cell Growth & Differentiation, and Cancer Epidemiology, Biomarkers & Prevention at reduced member rates; beginning in 1998 associate members will be able to purchase AACR journals for half the price of a regular member subscription;

3. an advance copy of the scientific Program and (if one has been purchased by the associate member) the Proceedings of the American Association for Cancer Research that contains over 4,000 abstracts of proffered papers presented at the annual meeting;

4. the privilege of registering for the annual meeting at the low associate member rate;

5. the privilege of electing an Associate Member Council that organizes programs benefitting associate members and that presents their concerns to the AACR Board of Directors;

6. the opportunity to stand for election to the Associate Member Council;

7. preferred access to the AACR Employment Register;

8. priority notification of events in the AACR's series of special conferences on timely subjects in the field;

9. substantially reduced registration rates at special conferences;

10. the receipt of AACR newsletters, meeting announcements, and an up-to-date Membership Directory;

11. the opportunity to participate in three Summer Workshops that foster knowledge in the cancer field for young investigators; and

12. the facilitation of informal scientific exchange with leading researchers in the cancer field.

PROCEDURES FOR APPLICATION

Persons wishing to apply for associate membership must use the official application form on the reverse side of these instructions. Each candidate for associate membership must be nominated by an active, corresponding, emeritus, or honorary member in good standing of the AACR. Three completed copies of the form should be submitted; at least one of these copies must carry the original signatures of both the candidate and the nominator. In addition, the candidate should submit one copy of his or her curriculum vitae. The application may be submitted to the Association Office at any time.

After review of applications for associate membership, the Executive Director will notify candidates of their election or deferral within one month of the receipt of the application form. A check for one year's dues payment must accompany the application. Dues for 1997 are $45 for associate members residing in the Americas and $55 for residents of other countries. This fee will be refunded to any candidate deemed to be ineligible for associate membership. Checks should be in U.S. currency, made payable to AACR, Inc., and drawn on a U.S. bank. Send the three copies of the application form and the appropriate dues payment to:

Membership Services Department
American Association for Cancer Research
Public Ledger Building, Suite 826
150 S. Independence Mall West
Philadelphia, PA 19106-3483
Phone: 215/440-9300
Fax: 215/440-9412
Email: aacr@aacr.org

RESPONSIBILITIES OF MEMBERSHIP

Associate members must pay annual dues in an amount to be determined by the AACR Board of Directors. Dues for 1997 have been set at $45 per year for residents of the Americas and $55 for residents of other countries. If an application is submitted by August 31, the accompanying dues payment will be credited to the current year. Candidates submitting applications between September 1 and December 31 may indicate whether they wish their dues payments credited to the current or forthcoming year. Candidates should be aware, however, that associate members may sponsor an abstract for the annual meeting only if their dues for the current year are paid. For example, an associate member submitting an abstract in October 1997 for the forthcoming annual meeting must have paid dues for 1997. Any newly elected associate members of the AACR who have already purchased subscriptions to Cancer Research, Clinical Cancer Research, Cell Growth & Differentiation, or Cancer Epidemiology, Biomarkers & Prevention at the higher, nonmember rate will receive a refund for the unused portion of that subscription upon receipt of their payment for a member's subscription.

Each Fall the AACR will send to current associate members an invoice for dues for the forthcoming year. Payment of this invoice must be accompanied by a statement signed by the associate member's registrar, dean, or department head, verifying the member's current academic status. The Association's By-Laws state that dues are payable for each year in advance by January 1 of the year to which they should be applied. An individual may be an associate member for a maximum of five years. Each year in which an individual pays dues will count as one full year of associate membership. Thus, an associate member who pays dues for 1997 may retain associate membership until December 31, 2001. The Board of Directors may terminate the membership of an associate member whose dues are in arrears for two years.

Margaret Foti, Ph.D.
Executive Director
NAME OF CANDIDATE:  

DATE OF BIRTH:  

INSTITUTIONAL AFFILIATION:  

INSTITUTIONAL ADDRESS:  

(City)  (State/Province)  (Country)  (Postal Code)  

TELEPHONE NUMBER:  

IF outside the United States list country and city codes.  

FAX NUMBER:  

E-MAIL ADDRESS:  

PRESENT ACADEMIC STATUS/TITLE (Please check only one):  

____ Graduate Student  

____ Medical Student  

____ Physician in Training  

____ Postdoctoral Fellow  

PRIMARY FIELD OF RESEARCH (Please check only one):  

____ Biochemistry and Biophysics  

____ Biostatistics  

____ Carcinogenesis  

____ Cellular Biology and Genetics  

____ Clinical Investigations  

____ Endocrinology  

____ Epidemiology  

____ Immunology  

____ Molecular Biology and Genetics  

____ Preclinical Pharmacology and  

____ Virology  

____ Other:  

ACADEMIC DEGREES (Please indicate degree(s) acquired to date along with the name of the academic institution and date of receipt. Provide information on degree currently being sought and the anticipated date of completion of this degree program.)  

ACADEMIC DEGREES  

RELEVANT RESEARCH EXPERIENCE NOT RELATED TO COURSE WORK (Please list most recent first.)  

PUBLICATIONS (List the authors, title, journal, volume, inclusive pages, and year of any article in a peer-reviewed journal on which the candidate appears as an author. Do not list abstracts. Continue on a separate sheet, if necessary.)  

CANDIDATE NOMINATED BY*:  

(please print)  

SIGNATURES  

I hereby apply for associate membership in the American Association for Cancer Research. I have read the instructions on the reverse side of this form, and I understand the privileges and responsibilities of this class of membership. I certify that the statements on this application are true.  

Signature of Candidate:  

Date:  

I recommend this candidate for Associate Membership in the American Association for Cancer Research. To the best of my knowledge, the candidate is qualified for this class of membership, and the statements on this application are true.  

Signature of Nominator*:  

Date:  

Submit three copies of this form. At least one copy must contain the original signatures of the candidate and the nominator. In addition, submit one copy of your curriculum vitae. Enclose a check in U.S. funds, made payable to AACR, Inc., and drawn on a U.S. bank for one year's dues. For 1997 and 1998 dues are $45 for Associate Members residing in the Americas and $55 for residents of other countries.  

Check one of the following boxes only if this form is being submitted between September 1 and December 31:  

The enclosed dues payment should be applied to the  

☐ current calendar year  

☐ forthcoming calendar year.  

(NOTE: If dues are applied to the forthcoming year, membership will take effect on January 1, but the candidate will not be eligible to sponsor an abstract for presentation at the annual meeting in March or April of that year.) See Guidelines for Application on the reverse side of this form for further instructions.  

*Nominator must be Active, Corresponding, Emeritus, or Honorary member of the AACR in good standing.
<table>
<thead>
<tr>
<th>AUDIO CASSETTE DISCOUNTS</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>1 - 5 cassettes</td>
<td>$11.50</td>
</tr>
<tr>
<td>6 - 11 cassettes</td>
<td>5% discount</td>
</tr>
<tr>
<td>12 - 24 cassettes</td>
<td>10% discount</td>
</tr>
<tr>
<td>25 - 48 cassettes</td>
<td>15% discount</td>
</tr>
<tr>
<td>49+</td>
<td>20% discount</td>
</tr>
</tbody>
</table>

*CASSETTES ARE LISTED BEFORE PROGRAM TITLES*

CANC 700 (3 cass., $34.50) Public Session: Progress and New Hope in the Fight Against Cancer: A Public Forum Featuring the Latest Discoveries
CANC 701 (2 cass., $23) Educational Session 2: Cancer Research in the Post-Genome Era
CANC 702 (3 cass., $34.50) Methods Workshop 1: Bioinformatics in Cancer Research
CANC 703 (2 cass., $23) Methods Workshop 2: Differential Display in Gene Discovery and Functional Analysis
CANC 704 (2 cass., $23) Methods Workshop 3: Protein-Protein Interactions
CANC 705 (2 cass., $23) Educational Session 4: Nonviral Delivery Systems for Gene Therapy
CANC 706 (2 cass., $23) Educational Session 5: The Biology of Cancer Metastasis
CANC 707 (2 cass., $23) Educational Session 1: Genetics and Biochemistry of Programmed Cell Death
CANC 708 (2 cass., $23) Educational Session 3: Telomerase, Cellular Senescence, and Cancer
CANC 709 (1 cass., $11.50) Meet-the-Expert Sunrise Session: Molecular Approaches to the Management of Ovarian Cancer (Rober C. Brist, Jr.)
CANC 710 (1 cass., $11.50) Meet-the-Expert Sunrise Session: Transcriptional Models and Drug Discovery (Winston G. Keel, Jr.)
CANC 711 (1 cass., $11.50) Meet-the-Expert Sunrise Session: Research Issues and Special Populations (Ott W. Brawley)
CANC 712 (1 cass., $11.50) Meet the Expert Sunrise Session: Cancer Vaccines (David E. Carbone)
CANC 713 (1 cass., $11.50) Meet-the-Expert Sunrise Session: Chemoprevention in Transgenic Animals (James M. Phang)
CANC 714 (1 cass., $11.50) Meet-the-Expert Sunrise Session: Advances in Stem Cell Transplantation (Elizabeth J. Shpall)
CANC 716 (2 cass., $23) Plenary Session: Genetic Predisposition to Cancer
CANC 717 (1 cass., $11.50) Presentation by the Director of the National Cancer Institute (Richard D. Klausner)
CANC 718 (1 cass., $11.50) Thirty-Seventh G.H.A. Clowes Memorial Award Lecture: "bel-2 Gene Family and the Regulation of Cell Death" (Stanley J. Kormayer)
CANC 719 (3 cass., $34.50) Minisymposium Pharmacology/Therapeutics 11: Molecular Mechanisms Controlling Sensitivity to Antifolates
CANC 720 (3 cass., $34.50) Minisymposium Radiobiology/Radiation Oncology 2: Genetic Determinants of Cellular Response to Radiation
CANC 721 (2 cass., $23) Minisymposium Biology 6: Proteinsases: Invasion and Regulation
CANC 722 (2 cass., $23) Minisymposium Epidemiology/Prevention 2: Genetic Susceptibility
CANC 723 (2 cass., $23) Symposium 1: Genes, Cell Proliferation, and Antineoplastic Drugs
CANC 724 (2 cass., $23) Symposium 2: Acute Myeloid Leukemia
CANC 725 (2 cass., $23) Symposium 3: New Techniques for Molecular Diagnostics
CANC 726 (2 cass., $23) Symposium 4: Behavioral and Psychosocial Methods in Cancer Epidemiology and Control
CANC 727 (1 cass., $11.50) Second Joseph H. Burchenal AACR Clinical Research Award: "Antigen Receptors as Targets for Immunotherapy of Lymphoma" (Ramon T. Xavier)
CANC 728 (2 cass., $23) Minority Issues Committee Cancers Symposium
CANC 729 (1 cass., $11.50) Meet-the-Expert Sunrise Session: Advances in the Management of AIDS-related Malignancies (Ellen G. Friedl)
CANC 730 (1 cass., $11.50) Meet-the-Expert Sunrise Session: How to Get Your New Idea into the Clinic — Experiences with Antiangiogenesis Agents (Elia K. Kohn)
CANC 731 (1 cass., $11.50) Meet-the-Expert Sunrise Session: The Biological Basis of the New International Classification of Lymphomas (Elinor S. Jaffe)
CANC 732 (1 cass., $11.50) Meet-the-Expert Sunrise Session: FHIT Gene Alterations in Cancer (Kay Heschle)
CANC 733 (1 cass., $11.50) Meet-the-Expert Sunrise Session: Advances in Oncoprotein Imaging (Michael J. Welch)
CANC 734 (1 cass., $11.50) Meet-the-Expert Sunrise Session: Cancer Survivorship Research (Anna T. Meadows)
CANC 735 (1 cass., $11.50) Meet-the-Expert Sunrise Session: p53 and Genetic Instability (Jeffrey M. Wahl)
CANC 736 (2 cass., $23) Symposium 5: Demystifying the Role of Cytokines in Tumor Immunobiology: Status and Future Utility
CANC 737 (2 cass., $23) Symposium 6: Epidemiology and Pathogenesis of Secondary Cancers
CANC 738 (2 cass., $23) Symposium 7: Animal Models for Functional Analysis of Tumor Suppressor Genes
CANC 739 (3 cass., $34.50) Minisymposium Pharmacology/Therapeutics 17: Molecular Mechanisms of Drug Resistance
CANC 740 (2 cass., $23) Minisymposium Molecular Biology/Biochemistry 11: Novel Tumor Suppressor Genes and New Interactions of Known Tumor Suppressor Genes
CANC 741 (2 cass., $23) Minisymposium Clinical Investigations 4: Clinical Relevance of p53 Mutations
CANC 742 (3 cass., $34.50) Minisymposium Carcinogenesis 6: Gene Regulation in Tumor Initiation, Promotion, and Progression
CANC 743 (1 cass., $11.50) Controversy Session 1: What is the Role of Prophylactic Surgery in Breast and Ovarian Cancer?
CANC 744 (1 cass., $11.50) Presentation of the Fifth Gertrude Elion Cancer Research Award
CANC 745 (1 cass., $11.50) Sixth American Cancer Society Award Lecture on Cancer Epidemiology and Prevention: "Etiologic Natural History, Management, and Molecular Genes of HNF1CC (Lynch Syndromes): Genetic Counseling Implications" (Henry T. Lynch)
CANC 747 (2 cass., $23) Minisymposium Biology 14: Regulation of Apoptosis
CANC 748 (3 cass., $34.50) Minisymposium Immunology/Biological Therapy 7: Tumor Antigen Presentation, Gostimulation, Normal and Abnormal T-Cell Activation
CANC 749 (3 cass., $34.50) Minisymposium Molecular Biology/Biochemistry 15: Regulation of Gene Expression in Signal Transduction
CANC 750 (2 cass., $23) Symposium 8: Prostate Cancer
CANC 751 (2 cass., $23) Symposium 9: Cell Cycle Regulation
CANC 752 (2 cass., $23) Symposium 10: Gene Interactions with the Environment/Carcinogenesis
CANC 753 (1 cass., $11.50) "NCL Listens": A Session Organized by the National Cancer Institute's Board of Scientific Advisors
CANC 754 (1 cass., $11.50) Annual Business Meeting of the American Association for Cancer Research, Inc.
CANC 755 (1 cass., $11.50) NCI Training Branch Workshop
CANC 756 (1 cass., $11.50) Meet-the-Expert Sunrise Session: Approaches to Using Genes as Cancer Therapies (Jack A. Roth)
CANC 757 (1 cass., $11.50) Meet-the-Expert Sunrise Session: Mechanisms Regulating p53 Function (Guillemmmmm Lezana)
CANC 758 (1 cass., $11.50) Meet-the-Expert Sunrise Session: Firnavel Transferase Inhibitors: Attacking the Molecular Basis of Cell Transformation (Allen J. Offdy)
CANC 759 (1 cass., $11.50) Meet-the-Expert Sunrise Session: Helicobacter pyloris as a Carcinogen (Yilovo Carvao)
CANC 760 (1 cass., $11.50) Meet-the-Expert Sunrise Session: New Approaches to Overcoming Multidrug Resistance (Alan F. Last)
CANC 761 (1 cass., $11.50) Meet-the-Expert Sunrise Session: Human Cancer Genes Travel to Cyberspace (Kenneth H. Butow)
CANC 762 (1 cass., $11.50) Meet-the-Expert Sunrise Session: DNA Methylation in Cancer (Stephen B. Baylin)
ICAN 763 (1 cas., $11.50) NIH Grants: So What’s New?
ICAN 764 (2 cas., $23) Symposium 11: Novel Clinical Trials Based on Genes and Molecular Therapeutics
ICAN 765 (2 cas., $23) Symposium 12: Identification and Management of Genetic High-Risk Individuals
ICAN 766 (2 cas., $23) Symposium 13: Mechanisms of Cellular Senescence
ICAN 767 (2 cas., $23) Symposium Pharmacology/Therapeutics 29: Drug Targeting
ICAN 768 (3 cas., $34.50) Minisymposium Endocrinology and Signal Transduction 5: Novel Pathways in Endocrine Signal Transduction
ICAN 769 (3 cas., $34.50) Minisymposium Clinical Investigations 9: From Biology to the Clinical Management of Breast Cancer
ICAN 770 (2 cas., $23) Minisymposium Biology 18: Regulation of Cell Cycle
ICAN 771 (1 cas., $11.50) Late-Breaking Research Session
ICAN 772 (1 cas., $11.50) Twenty-First Richard and Hinda Rosenthal Foundation Award Lecture: “There are no Bad Anticancer Agents - Only Bad Clinical Trial Designs” (Daniel D. Von Hoff)
ICAN 773 (1 cas., $11.50) Sixteenth Bruce F. Cain Memorial Award Lecture: “DNA Topoisomerases in Cell Proliferation and Cell Death (Lenny Feng Lin)
ICAN 774 (3 cas., $34.50) Minisymposium Pharmacology/Therapeutics 35: DNA Repair and Drug Resistance
ICAN 775 (3 cas., $34.50) Minisymposium Biology 23: Induction and Inhibition of Angiogenesis
ICAN 776 (3 cas., $34.50) Minisymposium Clinical Investigations 11: Applied and Molecular Biology for Diagnosis and Clinical Studies in Urological Malignancies
ICAN 777 (3 cas., $34.50) Minisymposium Epidemiology/Prevention 10: Biomarkers and Chemoprevention Studies
ICAN 778 (2 cas., $23) Symposium 14: Breast Cancer Genes (Tom Frank’s presentation not recorded)
ICAN 779 (2 cas., $23) Symposium 15: Apoptosis and Cancer Therapy
ICAN 780 (2 cas., $23) Symposium 16: Cellular Responses to Endogenous versus Environmentally Induced DNA Damage
ICAN 781 (1 cas., $11.50) DeWitt S. Goodman Lecture: “Methyl Insufficiency in Cancer” (Liamel A. Porier)
ICAN 782 (1 cas., $11.50) Sixteenth Cornelius P. Rhoads Memorial Award Lecture: Tumor Suppressor Gene Mutations in Mice (Tiler Jacks)
ICAN 783 (1 cas., $11.50) Meet-the-Expert Sunrice Session: Challenges in the Clinical Development of Growth-modulating Agents (Daniel D. Von Hoff)
ICAN 784 (2 cas., $23) Meet-the-Expert Sunrice Session: Barrett’s Esophagus: A Model of Human Neoplastic Progression (Brian J. Reid)
ICAN 785 (1 cas., $11.50) Meet-the-Expert Sunrice Session: Colon Cancer Genes (Stanley R. Hamilton)
ICAN 786 (1 cas., $11.50) Meet-the-Expert Sunrice Session: Retinoids and Cancer Chemoprevention (Wan Ke Hong)
ICAN 787 (1 cas., $11.50) Meet-the-Expert Sunrice Session: Recursion of Human Breast Epithelial Tumor Cells and Tumors by Manipulation of the Microenvironment: Implications for Epithelial Biology and Tumor Therapy (Mina J. Buesel)
ICAN 788 (1 cas., $11.50) Meet-the-Expert Sunrice Session: Tumor Virology (Philip J. Browning)
ICAN 789 (1 cas., $11.50) Meet-the-Expert Sunrice Session: Transcriptional Control of Programmed Cell Death in the Genesis and Therapy of Human Acute Leukemias (A. Thomas Look)
ICAN 790 (1 cas., $11.50) Symposium 17: Diagnostic, Prognostic, and Therapeutic Aspects of Tumor Suppressor Genes

CAN 791 (2 cas., $23) Symposium 18: Signaling Pathways for Novel Therapeutics
CAN 792 (2 cas., $23) Symposium 19: Telomerase and Clinical Applications
CAN 793 (3 cas., $34.50) Minisymposium Pharmacology/Therapeutics 42: Thymidylate Synthase Inhibitors
CAN 794 (3 cas., $34.50) Minisymposium Immunology/Biological Therapy 12: Cancer Vaccines
CAN 795 (2 cas., $23) Minisymposium Carcinogenesis 16: Biomarkers in Risk Assessment
CAN 796 (3 cas., $34.50) Minisymposium Molecular Biology/Biochemistry 26: Signal Transduction II
CAN 797 (1 cas., $11.50) Controversy Session 2: Estrogen Replacement Therapy: Beneficial or Harmful?
CAN 798 (1 cas., $11.50) Controversy Session 3: What Are the Appropriate Therapeutic Uses of Hematopoietic Growth Factors?
CAN 799 (2 cas., $23) Minisymposium Pharmacology/Therapeutics 44: Signal Transduction: Tyrosine Kinase Inhibitors
CAN 800 (2 cas., $23) Minisymposium Biology 29: TGFB
CAN 801 (3 cas., $34.50) Minisymposium Molecular Biology/Biochemistry 27: Telomerase II
CAN 802 (3 cas., $34.50) Minisymposium Carcinogenesis 17: Molecular Responses to DNA Damage
CAN 803 (2 cas., $23) Symposium 20: Metastasis, Invasion, and Angiogenesis: Mechanisms and Therapeutic Strategies
CAN 804 (2 cas., $23) Symposium 21: Colon Cancer

The following programs will be available on video cassette (Allow 4 - 6 weeks for delivery). Each video program consists of one cassette, $39.00

BONUS OPTION
Buy entire set of video cassettes, and receive a 10% discount.

Please complete and return entire form

Please print

SUB-TOTAL AUDIO TAPE ORDER $___
SUB-TOTAL VIDEO TAPE ORDER $___
(IL RESIDENTS ADD 8.75% SALES TAX) $___
AUD. $4.00 SHIPPING & HANDLING $4.00
VIDEO $4.00/TAPE inside U.S. $8.00 outside U.S. $8 & S & H ($24 MAX) $___
TOTAL (IN U.S. FUNDS) $___

NAME ___
ORGANIZATION ___
ADDRESS (NO PO BOXES) ___
CITY ___ STATE ___ ZIP ___
SIGNATURE ___
TELEPHONE ( )

Please note: Any defective tapes will be replaced, but tapes are non-refundable.

Send to: Teach 'Em, 160 East Illinois St., Chicago, IL 60611
Phone: (312) 467-0424 Fax: (312) 467-9271 Toll-Free: 1-800-225-3775
E-mail: teachem@bonus-books.com

CAN

The following programs will be available on video cassette (Allow 4 - 6 weeks for delivery). Each video program consists of one cassette, $39.00

CAN 744V (1 cas., $39)
- Presentation of the Fifth Gertrude Elion Cancer Research Award
- Presidential Address: "Cancer Genetics is a Little Like Insanity: We Have Gotten It from Our Kids! A Perspective on Past and Future Lessons from Genetic Studies of Childhood Cancer (Louise C. Strong)

CAN 745V (1 cas., $39) South American Cancer Society Award Lecture on Cancer Epidemiology and Prevention: "Etiology, Natural History, Management, and Molecular Genetics of HNFFC (Lynch Syndromes): Genetic Counseling Implications" (Henry T. Lynch)

CAN 772V (1 cas., $39) Twenty-First Richard and Hinda Rosenthal Foundation Award Lecture: "There are no Bad Anticancer Agents - Only Bad Clinical Trial Designs" (Daniel D. Von Hoff)

CAN 773V (1 cas., $39) Sixteenth Bruce F. Cain Memorial Award Lecture: "DNA Topoisomerases in Cell Proliferation and Cell Death (Lenny Feng Lin)

CAN 782V (1 cas., $39) Sixteenth Cornelius P. Rhoads Memorial Award Lecture: Tumor Suppressor Gene Mutations in Mice (Tiler Jacks)
SEPTEMBER 26-30, 1997
Tumor Suppressor Genes
Co-Sponsored by the National Cancer Institute of Canada
Chairpersons: Stephen H. Friend, Seattle, WA; Philip Branton, Montreal, Quebec, Canada
Victoria Conference Centre, Victoria, BC, Canada

OCTOBER 17-21, 1997
Transcriptional Control of Proliferation, Differentiation, and Development
Chairpersons: Robert N. Eisenman, Seattle, WA; Elaine V. Fuchs, Chicago, IL
The Sagamore Resort, Bolton Landing (Lake George), NY

DECEMBER 12-16, 1997
DNA Methylation, Imprinting, and the Epigenetics of Cancer
Chairpersons: Peter A. Jones, Los Angeles, CA; Stephen B. Baylin, Baltimore, MD; Timothy H. Bestor, New York, NY
El Conquistador Resort and Country Club, Las Croabas, PR

JANUARY 9-13, 1998
Molecular Mechanisms of Apoptosis Regulation
Chairpersons: John C. Reed, La Jolla, CA; Vishva M. Dixit, Ann Arbor, MI
Renaissance Esmeralda Resort, Indian Wells (Palm Springs), CA

JANUARY 24-28, 1998
Angiogenesis and Cancer
Chairpersons: Judah Folkman, Boston, MA; Michael Klagsbrun, Boston, MA
Hyatt Orlando, Orlando, FL

FEBRUARY 16-21, 1998
Innovative Molecular Biology Approaches to the Prevention, Diagnosis, and Therapy of Cancer
Joint Meeting with the Japanese Cancer Association
Chairpersons: Edward Bresnick, Worcester, MA; Kaoru Abe, Tokyo, Japan
Maui Marriott Resort, Maui, HI

MARCH 28-APRIL 1, 1998
89th Annual Meeting
Chairperson: Frank J. Rauscher III, Philadelphia, PA
Morial Convention Center, New Orleans, LA
Abstract Deadline: October 28, 1997

JUNE 14-18, 1998
Proteases and Protease Inhibitors in Cancer
Co-Sponsored by the Danish Society for Pathology
Chairpersons: Keld Dano, Copenhagen, Denmark; Henri Rochefort, Montpellier, France; Lynn M. Matrisian, Nashville, TN
Nyborg Strand Conference Center, Fyn, Denmark

AACR members will receive brochures on the above conferences as soon as they are available. Nonmembers should call or write:
American Association for Cancer Research
Public Ledger Building, Suite 826
150 South Independence Mall West
Philadelphia, PA 19106-3483
215-440-9300 • 215-440-9313 (FAX)
E-Mail: aacr@aacr.org
### 1998 AACR Annual Meeting Tentative Schedule of Events

#### Saturday, March 28, 1998
- **8:00 a.m.-1:30 p.m.**: Associate Member Council Grant Writing Session
- **9:00 a.m.-8:00 p.m.**: On-site Registration
- **10:00 a.m.-12:00 noon**: Public Session
- **12:00 noon-6:30 p.m.**: Educational Sessions
- **2:00-6:00 p.m.**: Methods Workshops
- **6:30-8:00 p.m.**: WICR Guest Lecture and Reception
- **8:00-10:00 p.m.**: Opening Mixer

#### Sunday, March 29, 1998
- **7:00 a.m.-4:00 p.m.**: On-site Registration
- **7:00-8:00 a.m.**: Meet-the-Expert Sunrise Sessions
- **8:00 a.m.-12:15 p.m.**: Opening Events
- **8:00-9:00 a.m.**: Presidential Address
- **9:00 a.m.-12:00 noon**: Plenary Session
- **12:00 noon-12:15 p.m.**: Elion Award Ceremony
- **8:00 a.m.-12:00 noon**: Poster Sessions
- **12:00 noon-5:00 p.m.**: Exhibit Show Kickoff
- **12:15 p.m.-1:15 p.m.**: Clove Award Lecture
- **1:15-5:15 p.m.**: Poster and Poster Discussion Sessions
- **1:30-5:00 p.m.**: Minisymposia
- **2:15-4:45 p.m.**: Symposia
- **5:30-6:30 p.m.**: AACR-Pezcoller Foundation Award Lecture
- **6:30-9:00 p.m.**: Minority Issues Committee Careers in Cancer Research Symposium
- **8:00-10:30 p.m.**: Annual Reception for All Registrants

#### Monday, March 30, 1998
- **7:00 a.m.-4:00 p.m.**: On-site Registration
- **7:00-8:00 a.m.**: Meet-the-Expert Sunrise Sessions
- **8:00-10:30 a.m.**: Symposia
- **8:00 a.m.-12:00 noon**: Poster and Poster Discussion Sessions
- **8:15-11:45 a.m.**: Minisymposia
- **10:00 a.m.-4:00 p.m.**: Exhibit Show
- **10:45 a.m.-12:15 p.m.**: Late-Breaking Research Session
- **12:15-1:15 p.m.**: Rosenthal Foundation Award Lecture
- **1:15-5:15 p.m.**: Poster and Poster Discussion Sessions
- **1:30-2:30 p.m.**: Cain Award Lecture
- **1:30-5:00 p.m.**: Minisymposia
- **2:45-3:45 p.m.**: Rhoads Award Lecture
- **4:00-6:30 p.m.**: Symposia

#### Tuesday, March 31, 1998
- **7:00 a.m.-4:00 p.m.**: On-site Registration
- **7:00-8:00 a.m.**: Meet-the-Expert Sunrise Sessions
- **8:00-10:30 a.m.**: Symposia
- **8:00 a.m.-12:00 noon**: Poster and Poster Discussion Sessions
- **8:15-11:45 a.m.**: Minisymposia
- **10:00 a.m.-4:00 p.m.**: Exhibit Show
- **10:45 a.m.-12:15 p.m.**: Late-Breaking Research Session
- **12:15-1:15 p.m.**: Rosenthal Foundation Award Lecture
- **1:15-5:15 p.m.**: Poster and Poster Discussion Sessions
- **1:30-2:30 p.m.**: Cain Award Lecture
- **1:30-5:00 p.m.**: Minisymposia
- **2:45-3:45 p.m.**: Rhoads Award Lecture
- **4:00-6:30 p.m.**: Symposia

#### Wednesday, April 1, 1998
- **7:00 a.m.-2:00 p.m.**: On-site Registration
- **7:00-8:00 a.m.**: Meet-the-Expert Sunrise Sessions
- **7:30 a.m.-11:30 noon**: Poster Discussion Sessions
- **8:00-10:30 a.m.**: Symposia
- **8:00 a.m.-12:00 noon**: Poster Sessions
- **8:15 a.m.-11:45 a.m.**: Minisymposia
- **9:00 a.m.-12:00 noon**: Exhibit Show
- **10:45 a.m.-12:00 noon**: Controversy Sessions
- **12:00 noon-4:00 p.m.**: Poster Discussion Sessions
- **12:15-3:45 p.m.**: Minisymposia
- **12:30-3:00 p.m.**: Symposia
- **4:00 p.m.**: Annual Meeting Ends
1998 PROGRAM COMMITTEE
Frank J. Rauscher III, Chairperson

CELL AND TUMOR BIOLOGY
Cell Growth Signaling Pathways:
Cell Biology Aspects
René St-Arnaud, Chairperson
Cell Death Signaling
John C. Reed and Douglas R. Green,
Co-Chairpersons
Tumor Progression, Invasion, and Metastasis
Meenhard Herlyn, Chairperson
Host-Tumor Interactions: Angiogenesis and Microcirculation
Rakesh K. Jain, Chairperson

MOLECULAR BIOLOGY
Cancer Genetics I: New Loci and Mechanisms of Genomic Alterations
Daniel A. Haber, Chairperson
Cancer Genetics II: TumorSuppressor Genes: Structure and Function
W. Marston Linehan, Chairperson
Cancer Genetics III: Human and Retroviral Oncogenes: Structure and Function
E. Premkumar Reddy, Chairperson
Gene Expression and Epigenetic Regulation
Stephen B. Baylin, Chairperson
Gene Regulation and Transcriptional Control of the Cancer Phenotype
Alan Bernstein, Chairperson
Cell Cycle
Chairperson To Be Appointed
Viral Oncogenesis
Karl Münger, Chairperson

CARCINOGENESIS
Biomarkers, Premalignant Lesions, Risk Assessment
Kenneth Olden, Chairperson
Molecular Carcinogenesis: Metabolism, DNA Lesions, Mutagenesis, and Repair
Lawrence A. Loeb, Chairperson
Promotion and Progression
Saraswati Sukumar, Chairperson

EPIDEMIOLOGY
Analytical Epidemiology in Populations
Barbara S. Hulka, Chairperson
Genetic and Molecular Epidemiology
Barbara L. Weber and Fred F. Kadlubar,
Co-Chairpersons

PREVENTION
Preclinical Prevention Studies: Markers and Mechanisms
William G. Nelson V, Chairperson
Clinical Prevention Studies
Scott M. Lippman, Chairperson

CLINICAL RESEARCH
Phase I Clinical Trials
Robert L. Capizzi, Chairperson
Phase II-III Clinical Trials
Eric K. Rowinsky, Chairperson

Organ-Site Specific Studies: Preclinical Research (Tumor Biology/Translational Research/ Experimental Therapeutics)
John T. Isaacs, Chairperson
Clinical Pharmacology
Alex Matter, Chairperson
Modality-based Clinical Research
William N. Halt, Chairperson
Molecular Biology/Oncology in the Clinic
A. Thomas Look, Chairperson
Supportive Care and Psychosocial Aspects of Cancer
William G. Nelson V, Chairperson

ENDOCRINOLOGY/ PRECLINICAL AND CLINICAL
Molecular and Preclinical Endocrinology: Receptors and Signal Transduction
Lorraine J. Gudas, Chairperson
Clinical Endocrinology
Chairperson To Be Appointed

IMMUNOLOGY/PRECLINICAL AND CLINICAL
Tumor Immunobiology: Experimental and Preclinical
Drew M. Pardoll and Giorgio Trinchieri,
Co-Chairpersons
Clinical Immunology: Biological Therapy
Roy S. Weiner, Chairperson

PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
Drug Discovery: Design, Screening, and Delivery
Steven Grant and Ivan D. Horak,
Co-Chairpersons
Mechanisms of Drug Action
Herbert M. Pinedo, Chairperson
Drug Resistance I - Multidrug Resistance
Wayne D. Kohls, Chairperson
Drug Resistance II
Susan B. Horwitz, Chairperson
Pharmacology and Preclinical Toxicology
John S. Lazo, Chairperson
Therapeutic Agents I (Small Molecule Approaches)
O. Michael Colvin, Chairperson
Therapeutic Agents II (Biological Approaches)
Stanley T. Crooke, Chairperson
Experimental Gene Therapy
Jonathan W. Simons, Chairperson
Topoisomerases, Other DNA-reactive Agents, Tubulin Agents
Yung-chi Cheng, Chairperson

RADIOBIOLOGY/RADIATION ONCOLOGY
Experimental Radiobiology
Michael B. Kastan, Chairperson
Radiation Oncology, Preclinical and Clinical
C. Norman Coleman, Chairperson
AACR MINORITY SCHOLAR AWARDS IN CANCER RESEARCH

Supported by a generous grant from the Comprehensive Minority Biomedical Program of the National Cancer Institute (NCI)

AACR Minority Scholar Awards in Cancer Research are offered to eligible minority scientists wishing to attend the Annual Meeting and Special Conferences of the American Association for Cancer Research (AACR). The awards are supported by a generous grant from the Comprehensive Minority Biomedical Program of the National Cancer Institute (NCI). Those eligible for these awards are graduate and medical students, physicians-in-training, and postdoctoral students from minority groups considered underrepresented in cancer research by the NCI, i.e., African Americans, Alaskan Natives, Hispanic Americans, Native Americans, and Native Pacific Islanders.

The 89th AACR Annual Meeting will take place March 28 - April 1, 1998, in New Orleans, LA. This year's annual meeting will attract approximately 7,500 scientists from around the world, will provide the latest findings in the most rapidly developing areas of basic, clinical, and translational cancer research, and will feature major presentations from prominent scientists who are making important advances in the field. The deadline for receipt of applications for Minority Scholar Awards for the 89th AACR Annual Meeting is December 1, 1997.

Applications for Special Conference awards are due approximately two months before the date of the meeting. The AACR special conferences on focused topics in cancer research have gained wide recognition as unique opportunities for in-depth discussion of important scientific issues in attractive, informal resort environments. For Special Conferences only, minority faculty at the level of Instructor, Lecturer, or Assistant Professor are also eligible for these awards.

For Further Information:
Ms. Robin E. Felder, Membership Development Coordinator
AMERICAN ASSOCIATION FOR CANCER RESEARCH
Public Ledger Building, Suite 826
150 South Independence Mall West
Philadelphia, PA 19106-3483
Telephone: (215) 440-9300
FAX: (215) 440-9313
Email: felder@aacr.org
http://www.aacr.org
Guidelines for Submitting Disks
to
American Association for Cancer Research Publications

The word processing packages that we prefer are as follows:

MacWrite
Microsoft Word (DOS, Windows, and Macintosh)

WordPerfect (DOS, Windows, and Macintosh)
XyWrite (DOS and Windows)

Also acceptable:

Ability
AmiPro
Aa, S-TeX
Appleworks
ArborTeX
ArborText
ClarisWorks WP
CPT 8000
CTOS
Diablo
DisplayWrite
Duet
Einstein
Enable
EXP
Final Word
FullWrite
GemWord Plus
IBM Writing Assistant
Interleaf
LaTeX
Latex
Leading Edge
Lotus Manuscript
Lotus Write

Mass 11
MS Windows Write
MS Works
MS Works WP Mac
Multimate
Multimate Advantage
Nibia
Nisus (to ASCII file)
Notewrite
OfficeWriter
PC Write
PFS First Choice
Professional Write
Q&A Write
Quark XPress
RagTime MS Works
(to ASCII file)
Rich Text Format
RSG (to ASCII file)
Signature
SLITeX
SmartWhere
SmartWrite II

SoloWriter
Sprint
Stx
SunWrite
Symphony
TeX
Text EExecutive
Textures
Total Word
Troff
Volkswriter
VuWriter
Wang OIS
Wang WPS
Wang Writer
Window Works
Windows Write
WiziWord
Wordstar
Wordstar 2000
WriteNow
Xerox

Software packages that we are unable to translate:

FrameMaker
PageMaker

Ready, Set, Go
Scientific Writer

Disks produced on IBM or IBM-compatible computers are preferred, but those produced on some Apple or Wang computers can also be converted. Because of the file structures and internal coding, we cannot accept disks created on desktop publishing systems or those created on proprietary typesetting systems. We also cannot guarantee that all special characters can be translated. Tabular and mathematical material, such as equations, will not be captured from the disk but will be rekeyed.

To expedite work and for your own security, we do require that you submit a hard copy printout of the disk file. The tables and equations will be keyed from this hard copy. We also need to know the name of the file to be converted, the type of hardware (e.g., IBM PC) on which the files were created, the operating system (e.g., DOS 3.3), and the version of the software (e.g., WordPerfect 5.1) used to create the file.

PLEASE FILL OUT ALL INFORMATION ON REVERSE SIDE AND SUBMIT THIS FORM WITH YOUR DISK. DISKS WILL NOT BE PROCESSED WITHOUT THIS INFORMATION.
DISK SUBMISSION FORM

AACR journals are now using personal computers to copyedit manuscripts accepted for publication. When submitting a revised manuscript, authors are encouraged to submit an electronic disk of the paper along with the required four hard copy printouts. Disks will ultimately be returned to the authors.

See reverse for the word processing packages that can be accepted.

File preparation

Please be sure that the file you send is the most recent version of the manuscript and that it matches the most recently submitted printed copy. The file should contain all the parts of the manuscript in one file. Mathematical and tabular material, however, will be processed in the traditional manner and may be excluded from the disk file.

Note: AACR does not assume responsibility for errors in conversion of customized software, newly released software, or special characters.

Please label the outside of the disk with the journal name, the first author's name, a partial title of the manuscript, and the name of the computer file used to access the manuscript on disk. To process your disk efficiently, we need the following information. Please be sure to provide ALL the information.

Name used to access paper on disk: ______________________________________
Name of computer used (e.g., IBM/PS2): ___________________________________
Operating system and version (e.g., DOS 3.3): _________________________________
Word processing program and version (e.g., WordPerfect 5.0): ___________________
    [See reverse for acceptable programs.]

Manuscript number: _________________________________________________________
First author: ________________________________________________________________
Corresponding author (if different from first author): ____________________________
Telephone/FAX numbers: _____________________________________________________

This form (both sides) may be reproduced.
AACR SPECIAL CONFERENCE IN CANCER RESEARCH

Angiogenesis and Cancer

January 24-28, 1998
Hyatt Orlando
Orlando, FL

CONFERENCE CO-CHAIRPERSONS
Judah Folkman / Boston, MA
Michael Klagsbrun / Boston, MA

CONFERENCE PROGRAM

Keynote Address
Nicole Le Douarin / Nogent sur Marne, France

Blood Vessels and Development
Patricia D'Amore / Boston, MA
Donald E. Ingber / Boston, MA
Jeffrey M. Isner / Boston, MA

Mechanisms of Vasculogenesis and Angiogenesis
Werner Risau / Bad Nauheim, Germany
Peter Carmeliet / Leuven, Belgium
Douglas Hanahan / San Francisco, CA

VEGF and VEGF Receptors
Kari K. Allitalo / Helsinki, Finland
Harold F. Dvorak / Boston, MA
Napoleone Ferrara / S. San Francisco, CA
Kenneth A. Thomas / West Point, PA

Angiopoietin and TIE Receptors
George D. Yancopoulos / Tarrytown, NY
Bjorn R. Olsen / Boston, MA

Tumor Angiogenesis and Metastasis
Rakesh K. Jain / Boston, MA
Robert S. Kerbel / Toronto, Ontario, Canada
Isaiah J. Fidler / Houston, TX
Ann F. Chambers / London, Ontario, Canada

Inhibitors of Angiogenesis
Luisa Iruela-Arispe / Boston, MA
Noël Bouck / Chicago, IL
David A. Cheresh / La Jolla, CA

Clinical Applications
Noel Weidner / San Francisco, CA
Judah Folkman / Boston, MA

Application Deadline: October 13, 1997

Information and Application Forms:
American Association for Cancer Research
Public Ledger Building, Suite 826
150 South Independence Mall West
Philadelphia, PA 19106-3483
215-440-9300 215-440-9313 (FAX)
E-mail: aacr@aacr.org
Website: http://www.aacr.org
AMERICAN ASSOCIATION FOR CANCER RESEARCH

1998 AACR YOUNG INVESTIGATOR AWARDS TO SUPPORT ATTENDANCE AT THE ANNUAL MEETING

- Additional Awards Available for Asian Scientists -

• Corporate- and AACR-sponsored Young Investigator Awards are offered in support of travel to the AACR Annual Meeting by medical and graduate students, physicians-in-training, and postdoctoral fellows who are presenters of abstracts that have been highly rated by the Program Committee. The AACR-sponsored awards include the third AACR Gerald B. Grindey Memorial Young Investigator Award for a young scientist submitting an abstract in the field of preclinical science. Application for these awards is made on the Abstract Submission Form.

• A new program of Young Investigator Awards for scientists from Asia will be inaugurated in 1998. Sponsored by ITO EN, Ltd., these additional new awards are for scientists-in-training (see above) who are presenters of highly rated abstracts and who will be traveling to the Annual Meeting from Asia. Apply as above.

• Please note that the submission of an abstract by the deadline is absolutely required to be considered for the awards described above.

• AACR Minority Scholar Awards are offered to the Annual Meeting and AACR Special Conferences through the Comprehensive Minority Biomedical Program of the National Cancer Institute (NCI). Those eligible for these awards are graduate and medical students, physicians-in-training, and postdoctoral students from minority groups considered underrepresented in cancer research by the NCI, i.e., African Americans, Hispanic Americans, Native Americans, Native Pacific Islanders, and Alaskan Americans. Application deadline: December 1, 1997. Please call the AACR for an application form.

• Women In Cancer Research sponsors the WICR Brigid G. Leventhal Scholar Awards for graduate and medical students, physicians-in-training, and postdoctoral fellows who have submitted an abstract as presenting author for the AACR Annual Meeting. Application deadline: November 28, 1997. Call the AACR for application information.

• Young Investigator Awards are also available for a limited number of young scientists attending each of the AACR’s Special Conferences. For details, consult the conference brochure for each meeting, available on request from the AACR office.

Young scientists may also wish to obtain information about other relevant AACR programs including Associate Membership, research fellowships, the Employment Register, Mentorship Program for young minority investigators, and educational programs at the Annual Meeting and throughout the year. For more information, please contact:

AMERICAN ASSOCIATION FOR CANCER RESEARCH
Public Ledger Building, Suite 826
150 South Independence Mall West
Philadelphia, PA 19106-3483
Telephone: (215) 440-9300
FAX: (215) 440-9372 • E-mail: aacr@aacr.org